nctId,title
NCT00002651,Hormone Therapy in Treating Men With Stage IV Prostate Cancer
NCT00003553,Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
NCT00006199,"Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)"
NCT00020566,"Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma"
NCT00030264,Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
NCT00040222,"Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer"
NCT00054496,Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
NCT00074490,Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
NCT00084695,Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
NCT00092222,Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
NCT00114738,EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
NCT00129740,Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00150657,Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer
NCT00167180,Post Transplant Donor Lymphocyte Infusion
NCT00184015,"Bortezomib and Bevacizumab (""BB-mib-mab"") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)"
NCT00223665,Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy
NCT00254319,Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00267865,Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
NCT00290485,Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
NCT00292955,"Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma"
NCT00293475,Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL
NCT00301418,Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
NCT00301990,Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00303849,Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma
NCT00305682,Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
NCT00313599,Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT00316888,"Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer"
NCT00318513,Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema
NCT00338377,Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization
NCT00356031,Bevacizumab and Radiation Therapy for Sarcomas
NCT00368082,"Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)"
NCT00375674, A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
NCT00378638,Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer
NCT00406445,Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome
NCT00408772,"Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery"
NCT00411788,A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
NCT00461773,Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
NCT00463060,Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
NCT00489944,"Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma"
NCT00492505,"Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma"
NCT00492687,"Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas"
NCT00513474,Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
NCT00536991,"Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer"
NCT00538005,"Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma"
NCT00541047,Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)
NCT00547105,Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer
NCT00549848,Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
NCT00550992,Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
NCT00565851,"Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer"
NCT00566800,Erlotinib in Treating Patients With Barrett Esophagus
NCT00566995,Phase II Study of Vandetanib in Individuals With Kidney Cancer
NCT00569296," Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer"
NCT00570323,Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
NCT00573378,Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia
NCT00573989,"Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer"
NCT00574587,"Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis"
NCT00576654,Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT00577278,"Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma"
NCT00579683,Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer
NCT00585195,"A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer"
NCT00588770,Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00589420,Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
NCT00602329,MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
NCT00602602,"Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer"
NCT00602667,"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma"
NCT00602693,T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
NCT00608361, Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
NCT00610948,"Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment"
NCT00618657,"Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting"
NCT00620633,Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
NCT00621036,Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
NCT00625378,Sorafenib Long Term Extension Program (STEP)
NCT00651976,"Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery"
NCT00658658,Panitumumab Pediatric Study
NCT00660218,"A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer"
NCT00660621,"A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma"
NCT00665990,Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
NCT00669669,Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas
NCT00670046,"Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer"
NCT00671112,Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
NCT00679536,Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
NCT00680992,Study of Denosumab in Subjects With Giant Cell Tumor of Bone
NCT00690924,Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
NCT00694759,Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)
NCT00697632,Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
NCT00700414,International Pediatric Adrenocortical Tumor Registry
NCT00700882,"Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery"
NCT00702884,Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
NCT00717587,Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
NCT00718263,Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)
NCT00719875,HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
NCT00730158,"A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer"
NCT00733408,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
NCT00734877,"UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma"
NCT00740805,"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma"
NCT00747305,Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
NCT00756340,A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
NCT00759642,Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
NCT00761644,"Doxil, Bevacizumab and Temsirolimus Trial"
NCT00764972,Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer
NCT00770263, Erlotinib and Temsirolimus for Solid Tumors
NCT00776867,Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors
NCT00777036,A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
NCT00780494,"Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma"
NCT00781612,A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NCT00790816,Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
NCT00794950,Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
NCT00796978,Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
NCT00800345,Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors
NCT00812240,A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
NCT00814073,"A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap"
NCT00823459,Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma
NCT00826085,Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall
NCT00828009,BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00828919,Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials
NCT00829647,A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
NCT00831480,Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal
NCT00838955,Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
NCT00842257,Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
NCT00843037,Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
NCT00854152, A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
NCT00857389,Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
NCT00858377,A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
NCT00859781,177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
NCT00863122,Concentration and Activity of Lapatinib in Vestibular Schwannomas
NCT00866281,A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
NCT00871169,"Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer"
NCT00875238,Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
NCT00876993,Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
NCT00879437,Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas
NCT00885326,"N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma"
NCT00887068,Randomized Allogeneic Azacitidine Study
NCT00889954,Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
NCT00892190,Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome
NCT00892736,Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
NCT00900744,A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6
NCT00902044,Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
NCT00903461,Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma
NCT00903968,Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00904345,Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)
NCT00906516,Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
NCT00908167,Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
NCT00909831,Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
NCT00912340,Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer
NCT00915993,MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer
NCT00918333,"Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma"
NCT00918463,A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00921115,Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
NCT00923130,Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
NCT00923845,Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
NCT00923936,Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
NCT00925132,"Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat"
NCT00926640,A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
NCT00932451,"An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene"
NCT00936390,Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
NCT00936936,High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors
NCT00939523,Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
NCT00939770,Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
NCT00940316,Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
NCT00940381, Sirolimus and Cetuximab in Advanced Malignancies
NCT00942331,Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
NCT00942877,Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
NCT00946647,"A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)."
NCT00950365,Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00954174,"Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer"
NCT00956007,Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
NCT00957853,Preoperative Treatment With Cetuximab and/or IMC-A12
NCT00959868,A Study for Treatment of Superficial Bladder Cancer Using OGX-427
NCT00967655,"Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer"
NCT00968240,Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
NCT00968968,Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
NCT00970502,"Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer"
NCT00971737,Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer
NCT00975767,A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
NCT00976573,"Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma"
NCT00978250,A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
NCT00978432,Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT00979212,Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)
NCT00980460,Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
NCT00980954,Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
NCT00981890,Stereotactic Radiosurgery With Sunitinib for Brain Metastases
NCT00983398,"Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors"
NCT00983580,Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
NCT00984048,Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer
NCT00986661,A Study to Assess PV-10 Chemoablation of Cancer of the Liver
NCT00989651,"Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer"
NCT00990249,Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
NCT00993655," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer"
NCT00996385,Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
NCT00996892,"A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors"
NCT00997334,Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
NCT00998010,"Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma"
NCT00999401,A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
NCT01004224,A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
NCT01004861,Safety Study of PLX108-01 in Patients With Solid Tumors
NCT01005797,"Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers"
NCT01006369,"Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer"
NCT01007695,Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot
NCT01008150,Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
NCT01009918,Lisinopril or Coreg CR in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
NCT01010958,Adjuvant Valproate for High Grade Sarcomas
NCT01011439,Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
NCT01012817,"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer"
NCT01013649,Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
NCT01014065,A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect)
NCT01014598,Cisplatin in Treating Patients With Lung Cancer
NCT01014936," First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors"
NCT01015222,"Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies"
NCT01015833,Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT01016886,Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research
NCT01017640," Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors"
NCT01022086,Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab
NCT01023737,Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
NCT01025089,Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
NCT01026337,Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
NCT01027416,Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients
NCT01028222,A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
NCT01031381,"Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer"
NCT01032148,"Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma"
NCT01035099,RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
NCT01036087,"Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer"
NCT01037790,PD 0332991 in Treating Patients With Refractory Solid Tumors
NCT01038778,Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
NCT01042379,I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01042522,"Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors"
NCT01042535, Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
NCT01052363,OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas
NCT01058239,Bortezomib Plus Rituximab for EBV+ PTLD
NCT01058707,Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies
NCT01059552,Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01061515,Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
NCT01061788,"A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer"
NCT01063075,A Study in Advanced Solid Tumors
NCT01064479,Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck
NCT01064648,Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
NCT01064921,Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
NCT01067469,Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
NCT01075113,Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer
NCT01076543,Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT01077544,A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
NCT01079780,Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
NCT01081808,"Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors"
NCT01083966,Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma)
NCT01087554,Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
NCT01087983,Lapatinib With Sirolimus or Metformin
NCT01088815,Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
NCT01089101,Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
NCT01093573,Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
NCT01097278, S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer
NCT01099358,Study in Advanced Solid Tumors
NCT01099423,Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
NCT01104922,Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
NCT01106599,"A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors"
NCT01106872,"Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas"
NCT01106898,Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery
NCT01107522,Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT01107665,Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
NCT01108055,Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
NCT01111058,Everolimus Versus Placebo in Head and Neck Cancer
NCT01111188, Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma
NCT01111825,Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
NCT01112527,PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
NCT01113476,"Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies"
NCT01116336,Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck
NCT01116648,"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer"
NCT01118975,GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
NCT01120249,"S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery"
NCT01121588,"An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)"
NCT01122199,Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
NCT01124695,Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
NCT01128387,Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer
NCT01130077,A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
NCT01130519,A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
NCT01132014,Autologous OC-DC Vaccine in Ovarian Cancer
NCT01133678,Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck
NCT01138085,"Safety, Pharmacokinetics (PK) of AKT and MEK Combination"
NCT01139723,"A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors"
NCT01140568,Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
NCT01141478,Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
NCT01145430,"Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer"
NCT01146795,Neoadjuvant Therapy for Ovarian Cancer
NCT01146834,Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma
NCT01148849,Safety Study of MGAH22 in HER2-positive Carcinomas
NCT01149850,Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
NCT01154452,Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
NCT01156584,A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma
NCT01158521,Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
NCT01160211,"A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer"
NCT01162551,Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
NCT01163357,"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma"
NCT01164163,"INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease"
NCT01164228,Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
NCT01169636,"Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma"
NCT01173679,Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT01174121,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT01174199,Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
NCT01175356,"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin"
NCT01176474,A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
NCT01177397,"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma"
NCT01177683,Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
NCT01179269,Stage IIIB/IV Non-Small Cell Lung Cancer
NCT01180049,Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
NCT01182168,Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
NCT01182285,A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
NCT01182350,Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT01183559,"A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery"
NCT01184326,An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
NCT01187199,"Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer"
NCT01187810,"Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL"
NCT01188096,A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
NCT01188889,RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease
NCT01189643,"Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor"
NCT01191697,"CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer"
NCT01193842,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
NCT01194869,"Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer"
NCT01195922,Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
NCT01196390,"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer"
NCT01196936,Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
NCT01197170,Hormone Blockade in Combination With Targeted Agents
NCT01200238,STA-9090(Ganetespib) in Metastatic Ocular Melanoma
NCT01201538,A Study of Nilotinib in Growing Vestibular Schwannomas
NCT01201850,The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
NCT01202409,CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
NCT01203722,"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies"
NCT01206530,FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
NCT01207492,Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
NCT01208051,Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer
NCT01208103,Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
NCT01208662,"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65  (DFCI 10-106)"
NCT01210378,Nitroglycerin in Non-small Cell Lung Cancer
NCT01212822,Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
NCT01213238,"Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab"
NCT01215136,First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
NCT01216176,A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
NCT01216683,"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma"
NCT01217437,Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
NCT01217931,Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy
NCT01218048,ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01218555,Study of Everolimus (RAD001)in Combination With Lenalidomide
NCT01218867,Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes
NCT01219699," A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene"
NCT01221506,Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
NCT01222143,"Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia"
NCT01226316,"Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules"
NCT01231412,Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
NCT01231594,A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
NCT01233687,AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
NCT01236547,Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
NCT01237236,A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
NCT01238237,Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma
NCT01239134,Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
NCT01239368,Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
NCT01239732,A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer
NCT01240590,A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
NCT01241162,Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
NCT01241708,Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel))
NCT01244750,Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
NCT01246986,A Study of LY2157299 in Participants With Hepatocellular Carcinoma
NCT01248247,BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study
NCT01248949,A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
NCT01248962,"Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer"
NCT01249443,Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
NCT01251575,"Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant"
NCT01252251,RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
NCT01252667,Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
NCT01253460,"Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)"
NCT01253707,A Study of AMG 337 in Subjects With Advanced Solid Tumors
NCT01254864,Maximum Androgen Depletion
NCT01256398,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT01258855,Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT01259063,RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
NCT01260415,A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases
NCT01260506,Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
NCT01262027, TKI258 for Metastatic Inflammatory Breast Cancer Patients
NCT01263782,BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
NCT01263951,Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
NCT01264432,"Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer"
NCT01265030,A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
NCT01265433,Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy
NCT01266031,Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
NCT01266057,Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
NCT01266070, TKI 258 in Von Hippel-Lindau Syndrome (VHL)
NCT01266083,Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
NCT01267812,Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
NCT01269424,O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma
NCT01269853,Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
NCT01270321,A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
NCT01272037,"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer"
NCT01273155,Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
NCT01273610,Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer
NCT01274338,Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274624,Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
NCT01275677,Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
NCT01276041,"Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer"
NCT01276210,Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
NCT01281150,Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT01281176,High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT01281514,"Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer"
NCT01282502,Midostaurin (PKC412) for Locally Advanced Rectal Cancer
NCT01283048,Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
NCT01283789,Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
NCT01283945,"Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors"
NCT01285037,A Study of LY2801653 in Advanced Cancer
NCT01286272,Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
NCT01286987,"Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors"
NCT01287546,A Study of LY2875358 in Participants With Advanced Cancer
NCT01288430,"A Study of DS-2248, in Subjects With Advanced Solid Tumors"
NCT01290263,Amgen 386 for Recurrent Glioblastoma
NCT01292655,Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors
NCT01293032,Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
NCT01294670,Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients &lt; 21 Years at Diagnosis With Refractory Solid Tumors
NCT01294826,Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
NCT01295944,Carboplatin and Bevacizumab for Recurrent Ependymoma
NCT01296555,A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
NCT01296581, Safety Study of X-82 in Patients With Advanced Solid Tumors
NCT01296932,BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
NCT01297452,BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors
NCT01298570,Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
NCT01299636,Study of PM060184 in Patients With Advanced Solid Tumors
NCT01300962,Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
NCT01301391,Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
NCT01301807,Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)
NCT01302379,Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors
NCT01302405,Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
NCT01303341,Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma
NCT01303796,A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS)
NCT01305213,"Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer"
NCT01305499,A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)
NCT01305941,"A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases"
NCT01306045,"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies"
NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer
NCT01306643,"Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma"
NCT01307267,A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
NCT01307956,"Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer"
NCT01309126,Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
NCT01310231,A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
NCT01312376,Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
NCT01312857,"Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer"
NCT01313559,"Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer"
NCT01313897,"UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35)"
NCT01316757,"Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer"
NCT01319981,Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
NCT01320592,PD0332991/Paclitaxel in Advanced Breast Cancer
NCT01321346,A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
NCT01321437,Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
NCT01323517,Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
NCT01323751,Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
NCT01324180,"Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)"
NCT01324479,Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
NCT01325207,Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
NCT01325441,A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
NCT01326702," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors"
NCT01326871,A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
NCT01327612,Open Label Extension Study of Conatumumab and AMG 479
NCT01328054,A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
NCT01330966,Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
NCT01331135,Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
NCT01331291,Bosutinib in Adult Patients With Recurrent Glioblastoma
NCT01331616,Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
NCT01334502,"Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma"
NCT01336634,Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
NCT01336842,Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
NCT01338987,Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation
NCT01339039,Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
NCT01339871,Phase I Study of Pazopanib and Vorinostat
NCT01340300,Exercise and Metformin in Colorectal and Breast Cancer Survivors
NCT01342367,Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
NCT01343043,A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients With Synovial Sarcoma  (NY-ESO-1)
NCT01344824,"Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers"
NCT01345019,Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
NCT01345136,Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
NCT01345669,LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
NCT01346358,A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
NCT01347866,Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
NCT01349660,Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
NCT01351103,A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
NCT01351415,A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer
NCT01351909,Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT01352650,Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
NCT01353625,"Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies."
NCT01356290,Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT)
NCT01356628,A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
NCT01357161, A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)
NCT01358331,"A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)"
NCT01358877,A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
NCT01361113,Neoadjuvant Pazopanib in Renal Cell Carcinoma
NCT01362374,"Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors"
NCT01362803,AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
NCT01363817,Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT01366144,"Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction"
NCT01367002,Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
NCT01367665,STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
NCT01370109,Cardiovascular Effects of Sunitinib Therapy (CREST)
NCT01371981,Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01375699,"Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers"
NCT01375829,Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT01375842,A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01376310,GSK1120212 Rollover Study
NCT01376505,Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT01379534, A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
NCT01383148,Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
NCT01383538,FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
NCT01384253,Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
NCT01385228,"Pazopanib, Docetaxel, Prednisone Prostate"
NCT01386385,"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery"
NCT01386580,"An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma."
NCT01386710,Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
NCT01389778,Polycystic Ovary Syndrome Genetics and Treatment Response
NCT01390948,A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma
NCT01391143,Safety Study of MGA271 in Refractory Cancer
NCT01391533,Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors
NCT01391962,Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
NCT01392183,Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
NCT01392209,Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
NCT01392521, Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
NCT01393509,The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
NCT01396148,A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
NCT01396408,A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
NCT01396499,"Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias"
NCT01397734,Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
NCT01398462,Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
NCT01399918,Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
NCT01401959,Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
NCT01403610,Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
NCT01405391,Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
NCT01407198,Nilotinib With Radiation for High Risk Chordoma
NCT01407562,"Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors"
NCT01408043,"Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma"
NCT01409161,"Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin"
NCT01409174,IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
NCT01409200,Neoadjuvant Axitinib in Prostate Cancer
NCT01411410,Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
NCT01412229,Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT01414426,Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
NCT01415752,"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma"
NCT01416688,"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride"
NCT01418001,Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
NCT01420250,Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
NCT01420874,Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
NCT01421524,"Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma"
NCT01422746, Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess
NCT01424982,Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
NCT01425008,Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
NCT01427322,Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
NCT01427595, Effect of Metformin on Sensitivity of the Gonadotropin-releasing Hormone (GnRH) Pulse Generator to Suppression by Estradiol and Progesterone
NCT01428492,Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
NCT01430351,"Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)"
NCT01430416,Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
NCT01431209,Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
NCT01431794,Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
NCT01433991,E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
NCT01434303,"Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only"
NCT01434316,Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors
NCT01434602,Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
NCT01435395,"Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme"
NCT01436656,A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
NCT01436968,Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
NCT01437449,"Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
NCT01437566,Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
NCT01438112,Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
NCT01438554,"Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma"
NCT01439711,Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
NCT01439750,"Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)"
NCT01440582,Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
NCT01440998,"Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer"
NCT01441882,A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity
NCT01441947,Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
NCT01442935,Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
NCT01443468,Clinical and Genetic Studies of Li-Fraumeni Syndrome
NCT01443481,Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
NCT01445418,AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
NCT01445509,Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors
NCT01446809,Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
NCT01449058,A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
NCT01449279,Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
NCT01449370,Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer
NCT01449461,A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
NCT01450384,Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
NCT01450696,HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
NCT01450761,Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
NCT01453088,Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
NCT01453101,Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
NCT01453205,"A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"
NCT01454102,"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)"
NCT01455389,FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
NCT01456325,A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
NCT01456689,A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT01458067," A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency"
NCT01459211,Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)
NCT01459380,"Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer"
NCT01462630,Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
NCT01463046,Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
NCT01464086,LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome)
NCT01465659,Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
NCT01465802,Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
NCT01466036,Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT01466972,Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
NCT01467115,INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER
NCT01467310,Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
NCT01468896,"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery"
NCT01468922,Pazopanib and ARQ 197 for Advanced Solid Tumors
NCT01470131,A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
NCT01470209,A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
NCT01470404,Pharmacogenomic Study (Adjuvant Chemotherapy)
NCT01471054,Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma
NCT01471106,Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
NCT01471353,Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
NCT01471964,"Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer"
NCT01472016,Study of ABT-700 in Subjects With Advanced Solid Tumors
NCT01473095,Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
NCT01473901,A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT01473940,Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
NCT01476839,Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
NCT01478178,Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor
NCT01478321,Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
NCT01479244,Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
NCT01480154,"Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer"
NCT01480583,GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
NCT01482286,Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
NCT01482715,A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
NCT01482728,Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
NCT01483274,Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation
NCT01483690,A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
NCT01484041,Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
NCT01485042,Dose Escalation Study of Pazopanib Plus TH-302
NCT01485744,"LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer"
NCT01485861,Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
NCT01487265,Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
NCT01488318,Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
NCT01488552,Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
NCT01489813,Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
NCT01489865,ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
NCT01490749,Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
NCT01491737,"A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer"
NCT01492673,"Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma"
NCT01493505, TRINOVA-3
NCT01493843,Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
NCT01494662,HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
NCT01494688,A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors
NCT01495988,Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
NCT01497392," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers"
NCT01497444,Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
NCT01497626,Lapatinib and Bortezomib in Patients With Advanced Malignancies
NCT01497704,Dose-Escalation and Safety Trial of YN968D1
NCT01497808,RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma
NCT01498445,Phase I/II - Dasatinib and Decitabine
NCT01498484,Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
NCT01498978,Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01499121,Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
NCT01501487,MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
NCT01503229,Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01504126,Beta-Blocker / Ovarian
NCT01505569,Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
NCT01506596,Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
NCT01506609,The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
NCT01506973,A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer
NCT01508104,Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
NCT01508117,Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
NCT01510119,Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma
NCT01512251,BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
NCT01513083,A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
NCT01513733,The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer
NCT01514201,"Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas"
NCT01514864,Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
NCT01515527,Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
NCT01516216,Study of Vitamin D in Untreated Metastatic Colorectal Cancer
NCT01517243,Phase II Study of Alternating Sunitinib and Temsirolimus
NCT01517802,A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
NCT01518413,Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
NCT01519323, BRIM-P
NCT01519869,"Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma"
NCT01520389,Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
NCT01522768, Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
NCT01522820,Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
NCT01522872,Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
NCT01522989,"PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies"
NCT01523977,Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL
NCT01524978,A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers
NCT01525082,"Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors"
NCT01525550,A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
NCT01525589,A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
NCT01525602,Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
NCT01526096,Stem Cell Transplantation for Patients With Multiple Myeloma
NCT01526473,A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901
NCT01526603,High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
NCT01526837,Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
NCT01526928,"Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients"
NCT01528046,Metformin in Children With Relapsed or Refractory Solid Tumors
NCT01528345,"Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer"
NCT01529593,Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
NCT01529827,"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies"
NCT01530984,Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
NCT01531361,Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer
NCT01531894,Continuation Study of the Oral AKT Inhibitor GSK2110183
NCT01532011,Erlotinib in Combination With Pralatrexate in Advanced Malignancies
NCT01532089,Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations
NCT01532687,Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
NCT01532700, An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
NCT01532960,Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41)
NCT01533948,Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery
NCT01534260,"Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype"
NCT01534598,FdCyd and THU for Advanced Solid Tumors
NCT01534897,Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436
NCT01535053,Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
NCT01535157,Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
NCT01536743,A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
NCT01537107,Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery
NCT01537744,"A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer"
NCT01538680,Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
NCT01540253,"PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic"
NCT01540526,Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
NCT01540682,MLN8237 in Head and Neck Cancer
NCT01543581,Vismodegib for Treatment of Basal Cell Carcinoma
NCT01543698,A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
NCT01543763,"Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors"
NCT01543776,Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
NCT01545648,Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
NCT01545947," Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer"
NCT01546038,A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT01547546,A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
NCT01547806,Collection of Transplant Stem Cells for Plasma Cell Myeloma
NCT01548144,Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
NCT01548807,Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
NCT01551745, Salvage Ovarian FANG Vaccine + Bevacizumab
NCT01552356,Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
NCT01552434,"Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab"
NCT01553071,Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
NCT01553188,AMG 386 and Abiraterone for Advanced Prostate Cancer
NCT01553851,GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
NCT01553942,Afatinib With CT and RT for EGFR-Mutant NSCLC
NCT01555489,Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
NCT01556490,Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
NCT01556776,A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
NCT01560416,Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
NCT01560923,Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
NCT01561482,Study of Metformin With Simvastatin for Men With Prostate Carcinoma
NCT01562275," A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors"
NCT01562873, Ruxolitinib in Patients With Breast Cancer
NCT01562899, A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
NCT01564251,A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
NCT01565083,A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
NCT01565837,Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
NCT01566721,A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)
NCT01567930,Temsirolimus as Second-line Therapy in HCC
NCT01569984,Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis
NCT01570036,Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
NCT01570868,Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
NCT01571024, BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
NCT01571284,Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
NCT01572038,A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)
NCT01572727,"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation"
NCT01573702,Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
NCT01574729,Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma
NCT01575548,Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
NCT01576172,Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01576185,Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
NCT01576406,Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
NCT01576666,"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors"
NCT01577173,A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
NCT01577745,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors"
NCT01578109,Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
NCT01578551,A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
NCT01579812,"Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients"
NCT01579929,"Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)"
NCT01579994,Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
NCT01580410,Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
NCT01580969,"Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma"
NCT01581541, PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment
NCT01581970,Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head &amp; Neck Cancer
NCT01582009,Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
NCT01582191,Vandetanib With Everolimus
NCT01582204,Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
NCT01582295,XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
NCT01582672,Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
NCT01584531,"Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome"
NCT01585194,Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
NCT01585415, Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
NCT01585805,Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT01586195," Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E"
NCT01586611,A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer
NCT01587040,Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
NCT01587352,Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
NCT01587703,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers"
NCT01588184,An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
NCT01588431,Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
NCT01588678," A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas"
NCT01588821,Cabozantinib in Advanced Solid Malignancies
NCT01591421,P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.
NCT01591577,Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme
NCT01592370,Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
NCT01592383,Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
NCT01593228, Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
NCT01593254,Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib
NCT01593670,Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
NCT01593748,A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
NCT01594216, Ruxolitinib in Estrogen Receptor Positive Breast Cancer
NCT01596140,Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
NCT01596270,A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma
NCT01596751,Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
NCT01597388,AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
NCT01599754,Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
NCT01599832,Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
NCT01601535,Study of MLN8237 in Combination With Irinotecan and Temozolomide
NCT01602315,A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT01602406,Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
NCT01603004,Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors
NCT01603212," Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor"
NCT01604031,Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
NCT01606579,Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
NCT01606878,Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
NCT01607905,Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer
NCT01609556,"First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors"
NCT01609816,"Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant"
NCT01610206,A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
NCT01610284,Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
NCT01610570,Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
NCT01612351,Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
NCT01614197,A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
NCT01616303, A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
NCT01619761,Natural Killer (NK) Cells in Cord Blood Transplantation
NCT01619774, An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor
NCT01619813,Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
NCT01620190,Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
NCT01620216,Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients
NCT01620593,Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
NCT01621243,M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT01621477,T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
NCT01621490,PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1)
NCT01621542,Clinical Study of WT2725 in Patients With Advanced Malignancies
NCT01621568,Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
NCT01621906,18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib
NCT01622543,Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
NCT01622868,Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
NCT01623349,Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
NCT01624285,Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
NCT01624467,A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
NCT01624766,Anakinra or Denosumab and Everolimus in Advanced Cancer
NCT01625156,Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed By Surgery
NCT01625234,"Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer"
NCT01625260,A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
NCT01625286,"Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients"
NCT01625351,A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
NCT01625936,CRLX101 Plus Bevacizumab in Advanced RCC
NCT01627041,"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia"
NCT01628471,"MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer"
NCT01628640,Viral Therapy in Treating Patient With Liver Cancer
NCT01630590,Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
NCT01630733,"A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer"
NCT01631279, A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
NCT01633060,"A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi"
NCT01633541,Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
NCT01633970,A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01634217,Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
NCT01634685,"A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma"
NCT01634893,Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors
NCT01635712,Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies
NCT01636479,Phase 1 Safety Testing of SAR405838
NCT01636622," Study of Vemurafenib, Carboplatin, and Paclitaxel"
NCT01637090,Everolimus in Treating Cutaneous T-cell Lymphoma
NCT01638533,"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction"
NCT01638546,Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer
NCT01638676, A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
NCT01639248, A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer
NCT01639508,Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes
NCT01639911,MLN8237 and Pazopanib in Combination for Solid Tumors
NCT01640301,"Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant"
NCT01640665,Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
NCT01641939,A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
NCT01642251,Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer
NCT01642342,Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
NCT01643278,Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
NCT01643603,Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
NCT01643850,MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS)
NCT01644253,"Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia"
NCT01644773,Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
NCT01646125," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations"
NCT01647711,"A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations"
NCT01647828,A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
NCT01648348,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT01649180,NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801)
NCT01649284,Afatinib Expanded Access Program
NCT01649336,"A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer"
NCT01649778,Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
NCT01649947,Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
NCT01650506,Study of Erlotinib and Metformin in Triple Negative Breast Cancer
NCT01652079,CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
NCT01652196,Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
NCT01652482,A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
NCT01652976,"Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma"
NCT01653470,"Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors"
NCT01654965,Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
NCT01655225,A Study of LY3023414 in Participants With Advanced Cancer
NCT01655693,Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive)
NCT01655719,Pioglitazone in Thyroid Cancers
NCT01656538,A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
NCT01656642, A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf&#174;) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
NCT01657591, Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
NCT01657682,A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
NCT01658007,Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma
NCT01658553," A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212"
NCT01658878,"Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)"
NCT01659151, Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma
NCT01660451,"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas"
NCT01660906,"This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib"
NCT01660971,"Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery"
NCT01661283,Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
NCT01661400,Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors
NCT01661972,Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
NCT01662869,A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
NCT01663259,Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients
NCT01663272,A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
NCT01663857,A Study of LY2228820 for Recurrent Ovarian Cancer
NCT01664000,"A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors"
NCT01664182,"Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer"
NCT01664754,"Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer"
NCT01665768,Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
NCT01666730,Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
NCT01666756,Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
NCT01667419,BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
NCT01668719,"S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma"
NCT01669343,Aromatase Inhibitor Host Factors Study
NCT01669720,Adjuvant Aflibercept for Metastatic Colorectal Cancer
NCT01669798,"BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer"
NCT01670175,Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors
NCT01670877,Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
NCT01671904,"A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia"
NCT01672736,A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
NCT01673737, A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
NCT01674140,S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT01674270,Degarelix Neo-Adjuvant Radical Prostatectomy Trial
NCT01676714,Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
NCT01676753,Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
NCT01677559,Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
NCT01677741," The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects"
NCT01678105, A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
NCT01681433,OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
NCT01682083, A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.
NCT01682213,Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
NCT01683149, Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
NCT01683188, HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
NCT01683422,Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
NCT01683994,Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
NCT01684397,Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
NCT01685125,Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01685892,A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
NCT01686165,Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma
NCT01687179,Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
NCT01687400,Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT01687673,Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
NCT01688492,Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
NCT01688999,Cabozantinib for Advanced Urothelial Cancer
NCT01689974,Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma
NCT01689987,"Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma"
NCT01690468,PTX-200 and Carboplatin in Ovarian Cancer
NCT01690624,BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse
NCT01691898,A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)
NCT01693068,Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
NCT01693562,A Phase 1/2 Study to Evaluate MEDI4736
NCT01695005,A Study of LY3039478 in Participants With Advanced Cancer
NCT01695330,Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens
NCT01695473,Neoadjuvant BKM120 in High-risk Prostate Cancer
NCT01695941,"Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma"
NCT01696045,"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma"
NCT01697293,"Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer"
NCT01697566,An Endometrial Cancer Chemoprevention Study of Metformin
NCT01698905,Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
NCT01698918,"Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer"
NCT01700049,Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
NCT01700270, Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
NCT01700400," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer"
NCT01701037, Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
NCT01701674,Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
NCT01701986,Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
NCT01702064,Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
NCT01702558,A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer
NCT01702571,A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
NCT01703065,Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer
NCT01703390,Biomarker Directed Treatment in Metastatic Colorectal Cancer
NCT01703481,"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma"
NCT01703507,Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases
NCT01703572,A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
NCT01706458,Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
NCT01707004,Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01708161,A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
NCT01708798,Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
NCT01708941,Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT01708993," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy"
NCT01709292,Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
NCT01709435, Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors
NCT01709734,"A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer"
NCT01711515,Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer
NCT01711528,"Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma"
NCT01711541,Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
NCT01711632,"BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia"
NCT01711658,TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer
NCT01712217,A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
NCT01712659,Ruxolitinib for Adult T-Cell Leukemia
NCT01713946,A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3)
NCT01713972, Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
NCT01714115,Use of Eylea for the Treatment of an Optic Nerve Hemangioma
NCT01714739,A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
NCT01715285,"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)"
NCT01716416,Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT01716806,A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
NCT01717053,"Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer"
NCT01717482,Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
NCT01719250,Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01719302,"Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma"
NCT01719380,"Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer"
NCT01719744, Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma
NCT01720225,Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk
NCT01721577,Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
NCT01721603, A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases
NCT01722162,Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
NCT01722292,A Study of LY2940680 in Small Cell Lung Cancer
NCT01723020,A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
NCT01723202,Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
NCT01723774,PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
NCT01723800," PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer"
NCT01724606,Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
NCT01725100,"A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies"
NCT01725165,Oligometastatic Disease
NCT01726738,LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
NCT01727089, Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer
NCT01727154,Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
NCT01727336, Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma
NCT01727869, Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
NCT01728259,"First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD"
NCT01728311,Open Label Study of BAY1082439 in Patients With Advanced Cancer
NCT01729091,Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma
NCT01729338,Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
NCT01729845,"Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes"
NCT01729923,A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
NCT01730118,Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
NCT01730833,"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer"
NCT01730937,Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
NCT01730950,Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
NCT01732640,A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
NCT01732913,Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
NCT01732926,Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
NCT01733004,A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
NCT01734512,PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
NCT01734928,"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma"
NCT01736943,Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
NCT01737008,Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT01737502,PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer
NCT01738139,Ipilimumab and Imatinib Mesylate in Advanced Cancer
NCT01738451, A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors
NCT01738815,Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer
NCT01739764, An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
NCT01740297,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
NCT01740648,"Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer"
NCT01741727,A Study of ABT-414 in Subjects With Solid Tumors
NCT01741753,BKM120+Abiraterone Acetate for Metastatic CRPC
NCT01742286,"Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)"
NCT01742988,"Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma"
NCT01743950,A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
NCT01744223,Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
NCT01744340,A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
NCT01744652,Dasatinib and Crizotinib in Advanced Cancer
NCT01744665,Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.
NCT01745354,Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
NCT01746238,Bevacizumab/Doxorubicin/Radiation for Sarcoma
NCT01746251,Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
NCT01746849,Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
NCT01747551,FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
NCT01747876,Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma
NCT01748149,Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
NCT01748825,MK-1775 for Advanced Solid Tumors
NCT01749384,Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT01749397,"Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer"
NCT01750073,Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer
NCT01750281,Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
NCT01750567,A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
NCT01750918,BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
NCT01750983,Ipilimumab and Lenalidomide in Advanced Cancer
NCT01751425,Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
NCT01751451,"3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy"
NCT01752400,AUY922 for Advanced ALK-positive NSCLC
NCT01752920,Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors
NCT01753713,Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
NCT01754025,INHERIT EGFR - Studying Germline EGFR Mutations
NCT01754376,Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma
NCT01754987,A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
NCT01755195,Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
NCT01755767,Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy
NCT01756352,FET-PET for Evaluation of Response of Recurrent GBM to Avastin
NCT01757327,LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer
NCT01758731,Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
NCT01759303,Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
NCT01760525,A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
NCT01760655,Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
NCT01761266,"A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma"
NCT01762592,REDECT 2 REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
NCT01763164,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
NCT01764477,Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
NCT01764607,Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
NCT01765543,A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
NCT01765582,STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer
NCT01767194,Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
NCT01767454,Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
NCT01767623, A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients
NCT01767636,Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer
NCT01767766,Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT01767792,Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT01769391,A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
NCT01769547,A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
NCT01769768,Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
NCT01772004,Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
NCT01772472,A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
NCT01772797,Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
NCT01774253,Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
NCT01774344,Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE)
NCT01774786,A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
NCT01774851,"A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach"
NCT01775176, Effect of Weight and Insulin Sensitivity on Reproductive Function in Polycystic Ovary Syndrome
NCT01775423,A Study of BBI608 in Adult Patients With Advanced Malignancies
NCT01775501,Sorafenib + mFOLFOX for Hepatocellular Carcinoma
NCT01776008,Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
NCT01776307,A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
NCT01776723,A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
NCT01777776,Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
NCT01778439,A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
NCT01778920,Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)
NCT01778933,Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)
NCT01779050,Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
NCT01780545,Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
NCT01781026,Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
NCT01781429,"Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies"
NCT01781455,A Study of BBI503 in Adult Patients With Advanced Solid Tumors
NCT01781572,A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
NCT01783171,Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
NCT01783197, Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
NCT01783587,Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
NCT01783756,"Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis"
NCT01784068,Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NCT01784640,Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
NCT01784861,VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
NCT01786265,Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
NCT01786343,Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
NCT01787331,A Phase II Study of Itraconazole in Biochemical Relapse
NCT01787487,Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
NCT01787500,"Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers"
NCT01788280,Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
NCT01788566,A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer
NCT01789281,Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
NCT01790126,The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
NCT01790204,A Study of the Effects of PEITC on Oral Cells With Mutant p53
NCT01790503,A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT01790568,Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
NCT01791088,Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT01791478,BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
NCT01792050,Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
NCT01793948,Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer
NCT01794507,A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
NCT01794520,Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT01794702,"Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia"
NCT01794845,Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
NCT01796197,Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
NCT01797120,"Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI"
NCT01797523,RAD/Letrozole/Metformin
NCT01798485,A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
NCT01798901,AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia
NCT01799278,A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
NCT01799889,A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies
NCT01800695,Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
NCT01801111,A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment
NCT01801163,A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT01801358, A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
NCT01802320,Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
NCT01802632, AZD9291 First Time In Patients Ascending Dose Study
NCT01803282,Safety and Tolerability Study in Solid Tumors
NCT01804101,Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01804465,A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer
NCT01804530,Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors
NCT01804634,A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors
NCT01804686,A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01806064, A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT01806571,"Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia"
NCT01807065,Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
NCT01808573,A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
NCT01809691,"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer"
NCT01810016,NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
NCT01810913,"Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer"
NCT01811212,Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
NCT01811498,Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
NCT01812252,Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
NCT01812668,Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
NCT01813214, The Effects of Vemurafenib on Immunity in Patients With Melanoma
NCT01813734,Ponatinib in Advanced NSCLC w/ RET Translocations
NCT01814501,Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
NCT01814553, ADAM-Afatinib Diarrhea Assessment and Management
NCT01814813,Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
NCT01814826,Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older
NCT01815294, A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
NCT01815840,A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas
NCT01816035,Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
NCT01816984,PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT01817751,"Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma"
NCT01818986,Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
NCT01820325, Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
NCT01820364, LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
NCT01820754,Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
NCT01821729,Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
NCT01822015,"Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia"
NCT01822496,Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT01822509,Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
NCT01822522,Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
NCT01822613,Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
NCT01822652,"3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN"
NCT01822756,An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
NCT01823198,Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
NCT01823835,A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
NCT01824823,Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence
NCT01824836,Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer
NCT01825603,"ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery"
NCT01826448," A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma"
NCT01827111,Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
NCT01827137,WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
NCT01827384,Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors
NCT01828021,Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
NCT01828034,"First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma"
NCT01828112,LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
NCT01828476,Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
NCT01828554,Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight
NCT01829217,Sunitinib in Never-Smokers With Lung Adenocarcinoma
NCT01829503,Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT01829971,"A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection"
NCT01831089,"Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors"
NCT01831726,Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
NCT01832259,A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
NCT01833143,Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
NCT01833169,BKM120 for Patients With PI3K-activated Tumors
NCT01834248,DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01834651,A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
NCT01835145,Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
NCT01835158,Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
NCT01835184,Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery
NCT01835223,Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery
NCT01835288,Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01835626,Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
NCT01836029,Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT01837329,Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer
NCT01837602,cMet CAR RNA T Cells Targeting Breast Cancer
NCT01837667,Phase I Study of LB-100 With Docetaxel in Solid Tumors
NCT01837862,A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas
NCT01838395,Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
NCT01838577,Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
NCT01838642,Ponatinib for Advanced Medullary Thyroid Cancer
NCT01839955,Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer
NCT01840592,Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
NCT01841333,PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
NCT01841463,Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
NCT01841723,Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
NCT01841736,Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
NCT01842646,Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
NCT01843062,Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
NCT01843738,Radiation Use During Vemurafenib Treatment
NCT01843998,Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
NCT01844583,"Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib"
NCT01844674,A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
NCT01844765,"Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients."
NCT01844986,Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01845792,Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
NCT01846611,"A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
NCT01846624,Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01847001,Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
NCT01847274,A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
NCT01848067,"Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer"
NCT01848756,Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers
NCT01849146,"WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme"
NCT01849276,Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
NCT01849588,Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
NCT01849744,Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
NCT01849783,Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
NCT01849874,"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer"
NCT01850004,Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
NCT01850628,NSABP Biospecimen Discovery Project
NCT01852292,Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
NCT01853046,Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
NCT01853306,"A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors"
NCT01853423,Tuberou Sclerosis Complex: Facial Angiofibroma Skin Cream
NCT01853618,Tremelimumab With Chemoembolization or Ablation for Liver Cancer
NCT01853644,"Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer"
NCT01853748,T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
NCT01854034,Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
NCT01854606,Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
NCT01855750,"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma"
NCT01855828,Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
NCT01857193,Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer
NCT01857271,Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT01857934,Therapy for Children With Advanced Stage Neuroblastoma
NCT01858168,Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma
NCT01858389,A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
NCT01858883,Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
NCT01859026,A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
NCT01859741,A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
NCT01860430,A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer
NCT01860638,A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma
NCT01861314,"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia"
NCT01862081,"A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer"
NCT01862900,Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions
NCT01863550,Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01864096,The Metformin Active Surveillance Trial (MAST) Study
NCT01864746,A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
NCT01865747,A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
NCT01866293,Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
NCT01866410,Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
NCT01867333,Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
NCT01868022,"Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling"
NCT01868503,Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
NCT01869114,Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
NCT01869803,Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
NCT01870505,BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
NCT01870596,Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
NCT01870609,Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
NCT01870726,Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
NCT01871311,A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab
NCT01871571,"Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer"
NCT01871675,"Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies"
NCT01871766,"Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery"
NCT01871805,A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer
NCT01872260,"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer"
NCT01873833,"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer"
NCT01874353,Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874665,A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
NCT01874860,Skin Rash Study Before Chemotherapy in Colorectal &amp; Head and Neck Cancer Patients
NCT01875250,Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer
NCT01875666,"Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib"
NCT01875705,A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01876212,Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
NCT01876251, A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
NCT01876511,Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
NCT01876641,Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib
NCT01876784,"Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer"
NCT01876953,"Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia"
NCT01877083,Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
NCT01877382,"A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas"
NCT01877564,A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
NCT01877811,CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2
NCT01878617,A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
NCT01879085,Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma
NCT01880437,A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome
NCT01880567,Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)
NCT01880749,Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
NCT01882803,A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)
NCT01883362,Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
NCT01884285,AZD8186 First Time In Patient Ascending Dose Study
NCT01884740,Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age
NCT01885195,MEK162 for Patients With RAS/RAF/MEK Activated Tumors
NCT01885689,Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission
NCT01885897,IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
NCT01885949,Tivozanib + Enzalutamide in Adv Prostate Cancer
NCT01886859,Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT01887717,Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
NCT01887886,A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation
NCT01888302,"Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery"
NCT01888562,Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma
NCT01888965,Maintenance Dovitinib for Colorectal and Pancreas Cancer
NCT01889186,A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion
NCT01889420,"Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma"
NCT01890980,Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
NCT01891344,"A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)"
NCT01891747, A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma
NCT01892046,Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
NCT01892371,AC220 With 5-Aza or Low Dose Cytarabine
NCT01893320,Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
NCT01894061,NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
NCT01894451,Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
NCT01894672,"BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation"
NCT01895842,Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT01896531,A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT01896856,Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer
NCT01896869,"A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer"
NCT01896999,Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01897012,Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
NCT01897116, A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma
NCT01897441,Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
NCT01897571,Study of EPZ-6438 Formerly Known as E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas
NCT01898078, Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas
NCT01898130,Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
NCT01898494,Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer
NCT01898598,A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma
NCT01898715,Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
NCT01898793,Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT01899053,Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies
NCT01900002,Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)
NCT01900652,A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants
NCT01901146,Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac)
NCT01902173,"GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer"
NCT01902225,Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
NCT01903330,ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
NCT01903733,Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
NCT01903993,A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - &quot;POPLAR&quot;
NCT01904123,A Phase I Trial of WP1066
NCT01904903,Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt)
NCT01905046,Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer
NCT01905228,A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas
NCT01905592,"A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients"
NCT01905813,Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
NCT01907100,Nintedanib (BIBF 1120) in Mesothelioma
NCT01907802,Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction
NCT01907815,Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
NCT01908413,"Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma"
NCT01908426,Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
NCT01908478,"A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer"
NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma
NCT01910545,Phase 1 Study of OTS167 in Patients With Solid Tumors
NCT01911325,Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
NCT01911507,INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
NCT01912625,"Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery"
NCT01912963,"Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer"
NCT01913639,FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
NCT01914484,Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
NCT01914510,A Study of ENMD-2076 in Ovarian Clear Cell Cancers
NCT01914900,Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
NCT01915498,Phase 1 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation
NCT01915576,Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
NCT01915602,Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
NCT01916109,"Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer"
NCT01916135,"PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative"
NCT01916447,A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
NCT01918306,GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
NCT01918930,Tissue Procurement Substudy for Participants in Study CP-MGA271-01
NCT01919086,Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma
NCT01920061,A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents
NCT01921335,Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer
NCT01921751,High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
NCT01922076,WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
NCT01922752,To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors
NCT01922921,Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer
NCT01923168,"Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women"
NCT01923337,Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
NCT01924260,Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
NCT01924351,HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)
NCT01925131,"S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia"
NCT01925573,NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
NCT01926587,Oral Rigosertib in Combination With Azacitidine
NCT01927341,"Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors"
NCT01927627,Enzalutamide in Patients With High-risk Prostate Cancer
NCT01927744,"Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection"
NCT01928160,Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
NCT01928290,"Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer"
NCT01928394,"A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors"
NCT01928459,Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
NCT01928537,Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
NCT01928576,Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.
NCT01928589,Partial Breast Irradiation With Concurrent Chemotherapy for Women With Breast Cancer
NCT01929642,Rapalogues for Autism Phenotype in TSC A Feasibility Study (RAPT)
NCT01931098,Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM)
NCT01931150,Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
NCT01931163,NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
NCT01933815,Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
NCT01933932,Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933945,"Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib"
NCT01934335,Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
NCT01934361,Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
NCT01934894,Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
NCT01935336,Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
NCT01935921,"Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer"
NCT01935934,Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT01935947,Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT01935973,Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01936974,"(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma"
NCT01937117,Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
NCT01937715,A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
NCT01938573,"Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer"
NCT01938638,Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
NCT01939223,"COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST)"
NCT01939275,64Cu DOTA-Trastuzumab PET in Studying Patients With Gastric Cancer
NCT01940172,Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer
NCT01940276,Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
NCT01940809,"Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery"
NCT01941927,Trametinib With GSK2141795 in BRAF Wild-type Melanoma
NCT01942837,Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
NCT01942993,The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
NCT01943422,Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
NCT01943682,Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
NCT01943851,"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies"
NCT01945775,"A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)"
NCT01946204,A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer
NCT01946529,Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
NCT01946789,A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
NCT01947023,Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
NCT01947608,Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
NCT01948141,Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
NCT01948297,Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
NCT01949194,Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
NCT01949337,Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
NCT01949883,A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
NCT01950195,SRS (Stereotactic Radiosurgery) Plus Ipilimumab
NCT01950390,Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery
NCT01951690,Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
NCT01952054,Denosumab for Breast Cancer With Bone Mets
NCT01952249,A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
NCT01952847,Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis
NCT01953588,Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
NCT01953692,A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)
NCT01953926,"An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification"
NCT01954030,Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
NCT01954043,A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
NCT01954316,A Study of CFI-400945 Fumarate in Patients With Advanced Cancer
NCT01954576,NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
NCT01954732,Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
NCT01954784,Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
NCT01955434,SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01955499,Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT01956669,Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
NCT01956812,Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1)
NCT01957007,A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
NCT01958021,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)
NCT01958112,GSK1120212+GSK2141795 for Cervical Cancer
NCT01958658,"AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer"
NCT01959490,Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
NCT01959672,Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
NCT01959698,"Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma"
NCT01960023,Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
NCT01961115,INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
NCT01961765,Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01961843,Abiraterone Acetate for Castrate Resistant Prostate Cancer
NCT01962792,"Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma"
NCT01962896,A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
NCT01962948,"Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT01963481,Exemestane and Cyclophosphamide for Metastatic Breast Cancer
NCT01964300,Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery
NCT01964924,Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
NCT01965353,A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
NCT01966003,Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer
NCT01966289,SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
NCT01966445,"Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors"
NCT01966471,A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
NCT01967095,Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
NCT01967576,"Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma"
NCT01967810,ANG1005 in Patients With Recurrent High-Grade Glioma
NCT01968109,Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
NCT01968213,"A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer"
NCT01969643,A Safety Study of SGN-LIV1A in Breast Cancer Patients
NCT01970358,A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
NCT01970527,Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
NCT01970865,A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
NCT01970930,Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV &amp; ET) Patients
NCT01971489,"PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors"
NCT01971515,First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies
NCT01972217,Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer
NCT01972516,Tivozanib As Maintenance Therapy In GYN
NCT01973309,A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
NCT01973868,Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination
NCT01974258,"Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients"
NCT01974440,"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma"
NCT01974752,Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
NCT01974765,"Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies"
NCT01975519,A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
NCT01975701,A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
NCT01975831,A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
NCT01976169,Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
NCT01976585,In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
NCT01976741,Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor
NCT01977651,A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
NCT01977677,Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites"
NCT01979211,Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT01979523,Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
NCT01979536,Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
NCT01980823,Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
NCT01980875,Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
NCT01980888,Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia
NCT01981187,LGX818 for Patients With BRAFV600 Mutated Tumors
NCT01981525,A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome
NCT01981551,Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
NCT01982448,Cisplatin vs Paclitaxel for Triple Neg
NCT01983501,A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
NCT01983969,Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
NCT01984242,A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
NCT01985256,Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
NCT01985334,Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
NCT01985763,Genistein in Treatment of Metastatic Colorectal Cancer
NCT01986166,A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
NCT01986348,Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide
NCT01987362,"A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously"
NCT01987375,Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
NCT01987726,Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
NCT01987830,Bevacizumab w / Temozolomide PET &amp; Vascular MRI For GBM
NCT01988896,A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01989052,Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
NCT01989546,"Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations"
NCT01989585,"Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery"
NCT01989598,Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01989676,A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
NCT01990196,Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
NCT01990209,Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
NCT01990352,Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
NCT01991210,A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer
NCT01991379,MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
NCT01991938,Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
NCT01992653,"A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma"
NCT01992874,Relative Bioavailability of Pimasertib in Cancer Patients
NCT01993641,Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
NCT01993719,Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma
NCT01994369,Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17)
NCT01994382,Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma
NCT01994590,Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
NCT01995188,A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer
NCT01995708,"CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation"
NCT01996696,"A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer."
NCT01997255,Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
NCT01997333,"Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer"
NCT01997840,ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
NCT01998126,Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts
NCT01998971,A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
NCT01999270,Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
NCT01999738,Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
NCT01999972,A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
NCT01999985,Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
NCT02000596,Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC
NCT02000622,Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
NCT02000778,EC17 for Intraoperative Imaging in Occult Ovarian Cancer
NCT02000882,Capecitabine + BKM120 TNBC BC Brain Met
NCT02000934,A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies
NCT02000947,A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
NCT02002182,"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer"
NCT02002689,LDE225 for Patients With PTCH1 or SMO Mutated Tumors
NCT02003092,RX-5902 Treatment of Subjects With Solid Tumors
NCT02003209,"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer"
NCT02003573,Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
NCT02003924,Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
NCT02004028,Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.
NCT02004106,A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors
NCT02004262,Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
NCT02004522,A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
NCT02005289,"Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL"
NCT02005315,A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
NCT02005471,A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02006485,Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies
NCT02007044,Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT02007512,Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
NCT02008227,A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK
NCT02008383,Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
NCT02008877,A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST
NCT02009332,Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
NCT02009397,A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
NCT02009449,A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors
NCT02009631,A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
NCT02010021,Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.
NCT02010606,Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
NCT02010645,Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)
NCT02011945,A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
NCT02012231,"Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers."
NCT02012296,Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
NCT02013154,A Study of DKN-01 in Combination With Paclitaxel
NCT02013219,A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer
NCT02013804,A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
NCT02014116,A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
NCT02014337,Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
NCT02014636,Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
NCT02014909,A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors
NCT02015065,Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
NCT02015117,Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
NCT02015208,Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
NCT02015559,Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
NCT02015728,Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
NCT02016534,Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
NCT02016729,A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
NCT02017717,A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)
NCT02017964,"Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma"
NCT02018861,"A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies"
NCT02019069,CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02019576,Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
NCT02019693,A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
NCT02019979,Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO)
NCT02020070,"Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy"
NCT02020707,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
NCT02022007,Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis
NCT02022982,PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
NCT02023333,Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
NCT02023463,"Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer"
NCT02023905,Everolimus With and Without Temozolomide in Adult Low Grade Glioma
NCT02023996,PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
NCT02024087,Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
NCT02024607,A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
NCT02025010,Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.
NCT02025192,A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
NCT02025803,"A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors"
NCT02027935,Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4
NCT02027961,Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
NCT02028221,Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk
NCT02028988,Enzalutamide + External Beam Rt For Prostate
NCT02029417,"Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia"
NCT02029443,"ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia"
NCT02030483,Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
NCT02030964,N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
NCT02031419,"Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma"
NCT02031458,A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH
NCT02031536,Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
NCT02032277,A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
NCT02032810,Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
NCT02032823,Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
NCT02033148,Icotinib Hydrochloride in Treating Patients With Advanced Cancers
NCT02034110,Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
NCT02034123,Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
NCT02034552,A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
NCT02034916,"A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)"
NCT02035137,131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
NCT02035345,Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02035527,"Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck"
NCT02035787,Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
NCT02036086,Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
NCT02036476,Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02036502,A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
NCT02036918,Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
NCT02037230,Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas
NCT02038010,BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
NCT02038647,Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
NCT02038673,An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors
NCT02038699,A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
NCT02038946,Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
NCT02039726,An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects
NCT02039947,Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
NCT02040376,Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma
NCT02040857,Palbociclib + Endocrine Therapy for HR + BrCa
NCT02041260,A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
NCT02041429,Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
NCT02041481,"MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer"
NCT02041533,"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)"
NCT02042144,Safety and Effectiveness of Regorafenib
NCT02042378,A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
NCT02042430,"INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02042443,Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
NCT02042495,Endometrial Cancer Biomarker Changes Following Exposure to Metformin
NCT02042989,MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
NCT02043587,Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma
NCT02043665,Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM)
NCT02043678,"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms"
NCT02044120,"ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma"
NCT02044601,Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
NCT02044822,Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
NCT02045030,Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
NCT02045446,Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT02046122,Adoptive Transfer of Haplo-identical DLI for AML and MDS
NCT02046421,"Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02046538,Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
NCT02047149,Evaluating the Safety of Zileuton (Zyflo(R)) in Combination With Dasatinib (Sprycel (R) in Chronic Myelogenous Leukemia
NCT02047214,Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
NCT02047344,"Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC"
NCT02047747,A Phase II Study of Dacomitinib in Progressive Brain Metastases
NCT02048059,ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
NCT02048371,"A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas"
NCT02048384,A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
NCT02048488,"A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas"
NCT02048709,IDO Inhibitor in Advanced Solid Tumors
NCT02048722,"Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma"
NCT02048943,"Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer"
NCT02049515,A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
NCT02049541,Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
NCT02049593,PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
NCT02049801,"MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia"
NCT02049905,Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
NCT02049957,Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
NCT02050009,"Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02050321,A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
NCT02050919,"Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma"
NCT02051751,A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
NCT02051868,International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT)
NCT02052102,A Study to See Whether Breath-Hold Techniques During Radiation Radiation Treatment Are Effective in Helping to Improve Sparing of the Heart
NCT02052648,Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
NCT02052778,A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities
NCT02053376,A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
NCT02053636,A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
NCT02054520,Immunotherapy Study for Patients With Stage IV Melanoma
NCT02054806,Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)
NCT02055820,A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma
NCT02056015,A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
NCT02057107,"Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)"
NCT02057133,A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread
NCT02057640,MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
NCT02057770,Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02057939,Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
NCT02058706,LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer
NCT02059213, A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer
NCT02059265,"Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer"
NCT02060188,A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
NCT02060253,"Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer"
NCT02060370,Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
NCT02061332,DC Vaccine for Patients With Ductal Carcinoma In Situ
NCT02061397,Safety of Simvastatin in LAM and TSC
NCT02061761,Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies
NCT02063724,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant)
NCT02063958,Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
NCT02064036,Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate
NCT02064582,"Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer"
NCT02065063,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors"
NCT02065466,"Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases"
NCT02065609,89ZrTrastuzumab Breast Imaging With Positron Emission Tomography
NCT02065687,"Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer"
NCT02065765,International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
NCT02065869,Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
NCT02066181,Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
NCT02066532,Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
NCT02066636,A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)
NCT02067104,Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
NCT02067156,"Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma"
NCT02068079,A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
NCT02068586,Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
NCT02069093,"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer"
NCT02069145,Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
NCT02069730,A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
NCT02070406,"Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies"
NCT02070549,Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
NCT02071862,Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
NCT02071927,Study of the Glutaminase Inhibitor CB-839 in Leukemia
NCT02072486,Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT02073097,"Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma"
NCT02073123,Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
NCT02073487,Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel
NCT02073838,Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
NCT02073916,TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
NCT02073994,"Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation"
NCT02074839,Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074878,CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
NCT02075177,Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
NCT02075840,"ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients"
NCT02076152,FMISO PET Study of Glioblastoma
NCT02076191,Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
NCT02076997,Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate
NCT02077166,Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02077881,Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NCT02077933,"Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors"
NCT02077959,Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02078609,A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
NCT02078648,"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme"
NCT02078752,A Study Of PF-06647263 In Patients With Advanced Solid Tumors
NCT02079636,A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
NCT02079740,Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
NCT02080078,A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
NCT02080260,A Study of Regorafenib in Advanced Pancreatic Cancer Patients
NCT02081378,"A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)"
NCT02081495,A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
NCT02081755,Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
NCT02082210,A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
NCT02082665,Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam
NCT02082977,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma"
NCT02083250,Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia
NCT02083653,Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
NCT02083692,Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling
NCT02085070,MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
NCT02085148, A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
NCT02085408,Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02086526,Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)
NCT02086552,Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT02086695,Early Detection of Broken Hearts in Cancer Patients
NCT02087176,A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer
NCT02087241,Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
NCT02087423,A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)
NCT02088112,MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)
NCT02088541,Selinexor (KPT-330) in Older Patients With Relapsed AML
NCT02088684,Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
NCT02089230,"Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy"
NCT02089334,"Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer"
NCT02089685,Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)
NCT02090114,RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study)
NCT02090127,Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
NCT02091063,ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
NCT02091141,"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors"
NCT02091245,"Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML"
NCT02091531,Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
NCT02091960,"A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer"
NCT02092324,Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
NCT02092909,Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401)
NCT02093403,Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02093546,Translational Companion Protocol to GOG229O
NCT02094573,"A Phase 2, Multicenter, Randomized Study of AP26113"
NCT02094872,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
NCT02095054,Regorafenib and Cetuximab in Patients With Advanced Malignancy
NCT02095132,WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
NCT02095184,GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT02096055,4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)
NCT02096354,"A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer"
NCT02096471,MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1
NCT02097134,Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma
NCT02097225,"Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery"
NCT02097732,Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
NCT02097810,"A Phase 1/2a Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer; Study Targeting ALK, ROS1, or TRKA/B/C"
NCT02098109,Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
NCT02098343,"p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246"
NCT02098538,"Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma"
NCT02098967,"A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia."
NCT02099058,"A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors"
NCT02099539,A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma
NCT02099864,Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
NCT02100007,ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors
NCT02100423,Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02100852,"TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)"
NCT02101021,Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02101034,PD 0332991 and Cetuximab in Patients With Incurable SCCHN
NCT02101385,Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
NCT02101593,Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
NCT02101736,Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)
NCT02101775,"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
NCT02101788,Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
NCT02101853,Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101905,Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
NCT02101918,Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02101944,"Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma"
NCT02103478,Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS
NCT02104427,"PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients"
NCT02105350,A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
NCT02105636,Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
NCT02106507,ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
NCT02106546,"Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer"
NCT02107235,Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
NCT02107703,A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107755,Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT02108652,A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT02108782,Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
NCT02108964,"A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies"
NCT02109016,"A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer"
NCT02109445,Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies
NCT02109627,Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
NCT02109744,Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients
NCT02110069,A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
NCT02110082,Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
NCT02110355,A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
NCT02110563,"Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma"
NCT02111187,A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer
NCT02112032,Treatment of Advanced Melanoma With MK-3475 and Peginterferon
NCT02112916,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02113657,T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
NCT02113813,A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
NCT02113878,Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
NCT02114229,Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
NCT02115048,Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone
NCT02115243,Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
NCT02115282,Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
NCT02115464,Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy
NCT02115542,Single Agent Regorafenib in Refractory Advanced Biliary Cancers
NCT02115828,A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
NCT02116777,BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
NCT02116803,An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
NCT02116894,Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
NCT02116959,Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma
NCT02117024,A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
NCT02117219,Phase 1 Study to Evaluate MEDI4736 in MDS
NCT02117297,SCT Plus Immune Therapy in Average Risk AML/MDS
NCT02117362,Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
NCT02117479,Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
NCT02117648, A Study of LY2835219 in Participants With Cancer
NCT02117817,"Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer"
NCT02118285,"Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer"
NCT02118311,T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation
NCT02118337,"A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies"
NCT02119650,Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
NCT02119663,A Study of Ruxolitinib in Pancreatic Cancer Patients
NCT02119676,Study of Ruxolitinib in Colorectal Cancer Patients
NCT02120222,Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
NCT02120287,Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme
NCT02120417,A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
NCT02120469,Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
NCT02120677,Topical Itraconazole in the Treatment of Basal Cell Carcinoma
NCT02121418,"Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm"
NCT02121990,"Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer"
NCT02122172,Afatinib in Advanced Refractory Urothelial Cancer
NCT02122185,"Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02122770,"Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors"
NCT02122809,Phase I Study of Chiauranib in Patients With Advanced Solid Tumors
NCT02122861,"A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1"
NCT02122913,Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors
NCT02123758,A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT02124148,A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer
NCT02124421,"Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer"
NCT02124707,"Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN"
NCT02124772,"Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations"
NCT02124850,A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337
NCT02125084,Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
NCT02125357,Sequencing Abiraterone and Enzalutamide in mCRPC
NCT02125461,A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)
NCT02126553,Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission
NCT02126579,Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
NCT02127710,A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
NCT02128282,Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
NCT02128906,Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC
NCT02129062,Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
NCT02129075,CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
NCT02129101,Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies
NCT02129647,Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NCT02130466,A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022)
NCT02130557,"A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia"
NCT02130869,A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
NCT02131064,A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer
NCT02131584,Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL)
NCT02131597,SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS)
NCT02132598,Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
NCT02132754,Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
NCT02132949,"A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer."
NCT02133183,TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma
NCT02133742,"A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer"
NCT02134015,Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
NCT02134067,"Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors"
NCT02134886,Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
NCT02134912,S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
NCT02135133,"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL"
NCT02135757,Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients
NCT02136134,Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
NCT02137564,Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
NCT02137759,MRSI to Predict Response to RT/TMZ and Vorinostat in GBM
NCT02137837,"S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer"
NCT02138292,A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma
NCT02138383,Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
NCT02138617,Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
NCT02138786,Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT)
NCT02138812,Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
NCT02138929,LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
NCT02139215,Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients
NCT02139358,Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
NCT02139397,Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
NCT02140723,p53 and Response to Preoperative Radiotherapy for T2 and T3
NCT02140840,"A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib"
NCT02141282,A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
NCT02141295,A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE)
NCT02141477,Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
NCT02141542,Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
NCT02141828,A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
NCT02142218,Expanded Access Program With Nivolumab to Treat Melanoma
NCT02142296,Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
NCT02142530,Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
NCT02142738,Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
NCT02142803,MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
NCT02142868,"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate"
NCT02143050,"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients"
NCT02143401,Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
NCT02143414,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia"
NCT02143466,AZD9291 in Combination With Ascending Doses of Novel Therapeutics
NCT02143635,Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt
NCT02143726,"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer"
NCT02144038,Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma
NCT02145143,"Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib"
NCT02145559,A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
NCT02145910,Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
NCT02146066,Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
NCT02146222,VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
NCT02146833,Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma
NCT02146924,Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
NCT02147990,Open Label Safety and Efficacy Study of Rociletinib (CO-1686) in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI
NCT02149108,Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
NCT02150733,Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment
NCT02150967,"A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma"
NCT02151084,A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
NCT02151864,LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis
NCT02151981,AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT02152059,A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
NCT02152254,IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer
NCT02152631,A Study of LY2835219 in Participants With Previously Treated Lung Cancer
NCT02152943,"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients"
NCT02152982,Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT02152995,Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT02153450,Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
NCT02153580,"Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia"
NCT02154490,Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
NCT02154529,Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
NCT02154737,Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
NCT02154776,"Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)"
NCT02155088,BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer
NCT02155465,Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
NCT02155582,Copanlisib Pharmacodynamic Study
NCT02155647,Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
NCT02155920,Everolimus for Children With Recurrent or Progressive Ependymomaildren With Recurrent or Progressive Ependymoma
NCT02156804,"A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)"
NCT02157051,Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
NCT02157103,A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
NCT02157636,A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
NCT02157792,"An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy"
NCT02157883,"Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)"
NCT02158091,"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL"
NCT02158507,"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer"
NCT02158520,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
NCT02158858,"A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms"
NCT02159066,"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma"
NCT02159365,Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
NCT02159495,Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02159755,Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma
NCT02159950,Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02159989,MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
NCT02160015,"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"
NCT02160041,BGJ398 for Patients With Tumors With FGFR Genetic Alterations
NCT02160106,First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors
NCT02161419,RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
NCT02161770,Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
NCT02162719,A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
NCT02162888,"A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients"
NCT02163356,Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
NCT02163694,"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer"
NCT02163733,Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer
NCT02164006,"Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients"
NCT02164240,Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
NCT02164461,ADXS11-001 High Dose HPV+ Cervical Cancer
NCT02164838,VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
NCT02164916,S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
NCT02166905,"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission"
NCT02167854,"Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer"
NCT02168777,"Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer"
NCT02169284,Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
NCT02170389,Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
NCT02171286,The OncoPanel Pilot (TOP) Study
NCT02173093,Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma
NCT02174172,A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors
NCT02174549,Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
NCT02176161,Metformin Prostate Cancer Adjuvant Trial
NCT02177695,"S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer"
NCT02177812,A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
NCT02177825,Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
NCT02177838,Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
NCT02178072,"Window Trial 5-aza in HNSCC, T-tare"
NCT02178436,"Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer"
NCT02178644,Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer
NCT02178722,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)"
NCT02178956,A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
NCT02179086,Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179671,"Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer"
NCT02179918,A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
NCT02180698,TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery
NCT02180711,"An Open-label, Phase 1b Study of ACP 196 in Subjects With Follicular Lymphoma"
NCT02180724,"An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia"
NCT02180867,Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS)
NCT02181218,"Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas"
NCT02181478,Intra-Osseous Co-Transplant of UCB and hMSC
NCT02181738,Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205)
NCT02182622,LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
NCT02184195,Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
NCT02185690,"A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung"
NCT02186249,Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)
NCT02186301,TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
NCT02186509,Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
NCT02186821,Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
NCT02186834,Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
NCT02186847,Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT02187302,CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
NCT02187744,A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
NCT02187783,LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
NCT02187861,A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma
NCT02187991,Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
NCT02188264,Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
NCT02188368,Pomalidomide for Lenalidomide for Failures
NCT02188550,Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
NCT02188706,"A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)"
NCT02188745,ER Reactivation Therapy for Breast Cancer
NCT02189174,Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
NCT02189343,Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma
NCT02190695,"A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia"
NCT02192021,Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
NCT02192541,"Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas"
NCT02192775,UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
NCT02193152,Pazopanib in Molecularly Selected Patients With Advanced NSCLC
NCT02193282,Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193347,RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
NCT02194049,"Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer"
NCT02194829,Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT02195011,Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
NCT02195479,A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
NCT02195973,Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
NCT02196168,Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT02196181,Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
NCT02196857,Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation
NCT02197169,DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I)
NCT02197234,Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC
NCT02197247,"Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC"
NCT02197572,Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors
NCT02197897,Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
NCT02198417,Metformin Treatment in Polycystic Ovary Syndrome (PCOS)
NCT02199171,"Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer"
NCT02199197,Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer
NCT02199223,Regorafenib + Panitumumab
NCT02199236,Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management
NCT02199665,"Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma"
NCT02200380,A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
NCT02200562,Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
NCT02200614,Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer
NCT02200757,Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
NCT02200848,"Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL"
NCT02201212,Everolimus for Cancer With TSC1 or TSC2 Mutation
NCT02201355,"Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck"
NCT02201992,Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02202746,"A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer"
NCT02203513,"Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk"
NCT02203526,"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma"
NCT02203604,High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
NCT02203695,Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
NCT02203773,Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
NCT02204020,Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS
NCT02204072,BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
NCT02204085,"A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia"
NCT02204098,Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
NCT02204553,Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
NCT02204982,Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)
NCT02205333,A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
NCT02205398,"Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy"
NCT02205515,"An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis"
NCT02206763,Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT02206984,Endocrine Response in Women With Invasive Lobular Breast Cancer
NCT02207010,A Phase 0 Study of AZD1775 in Recurrent GBM Patients
NCT02207062,Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
NCT02207504,Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT02207530,Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN.
NCT02208037,Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
NCT02208375,mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer
NCT02210104,Adoptive Therapy Using Antigen-Specific CD4 T-Cells
NCT02210117,Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
NCT02211014,"An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma"
NCT02211222,An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
NCT02211755,Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
NCT02212561,Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
NCT02212730,A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
NCT02213042,Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
NCT02213107,Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/&gt; 65 Years Old With Prostate Cancer.
NCT02213289,PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
NCT02213744,MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
NCT02213926,"An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma"
NCT02214147,Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
NCT02215096,Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT02215161,Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide
NCT02215512,Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
NCT02216409,"Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody"
NCT02217566,"Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy"
NCT02218606,Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
NCT02219711,Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
NCT02219724,"A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors"
NCT02219737,Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02219789,Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
NCT02220608,Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
NCT02220842,A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
NCT02220855,A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
NCT02220894,Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
NCT02221310,Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
NCT02221739,Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT02221882,A Study of LY3164530 in Participants With Cancer
NCT02221960,A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
NCT02222688,UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02222922,A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
NCT02223247,"A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors"
NCT02223598,A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies  (CLC-102)
NCT02223819,Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02225405,"Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)"
NCT02225574,"An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)"
NCT02226276,Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
NCT02226965,Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL
NCT02227251,Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL)
NCT02227667,Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer
NCT02227914,Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
NCT02227940,Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer
NCT02228096,Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
NCT02228265,Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Enzalutamide
NCT02228369,"Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer"
NCT02228382,Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
NCT02228525,Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
NCT02228681,Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
NCT02228811,A Study of DCC-2701 in Participants With Advanced Solid Tumors
NCT02229136,Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
NCT02229149,"Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer"
NCT02229981,An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
NCT02230319,Prevention of Paclitaxel Neuropathy With Cryotherapy
NCT02231164,LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
NCT02231723,A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT02231749,Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02231775,Combi-Neo Study for Stage IV Melanoma
NCT02232230,A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
NCT02232243,HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
NCT02232620,A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
NCT02232633,A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
NCT02234115,"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma"
NCT02234180,Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy
NCT02234596,Nintedanib in Patients With Advanced Esophagogastric Cancer
NCT02234921,Pilot Study of DRibble Vaccine for Prostate Cancer Patients
NCT02234986,"A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma"
NCT02235324,"Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer"
NCT02235740,"A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)"
NCT02236000,A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
NCT02236013,A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02236195,Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
NCT02236572,"Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score"
NCT02237157,A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
NCT02238496,Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
NCT02238522,Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
NCT02239900,Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors
NCT02240238,"Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer"
NCT02240706,Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
NCT02240719,Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
NCT02241187,Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
NCT02241369,Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
NCT02241720,Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
NCT02242097,Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT02242942,A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02243371,GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
NCT02243917,A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors
NCT02244463,A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
NCT02244489,Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
NCT02246621,A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02247349,BMS-986012 in Relapsed/Refractory SCLC
NCT02248090,AZD9496 First Time in Patients Ascending Dose Study
NCT02248805,Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
NCT02249429,"Open-Label, Non Randomized Phase 2 Study With Safety Run-In"
NCT02250326,Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer
NCT02250781,Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors
NCT02250885,KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
NCT02251548,"A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia"
NCT02251821,JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
NCT02252042,Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
NCT02252146,Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation
NCT02252263,A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
NCT02252887,"Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab"
NCT02253420,COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients
NCT02253992,Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
NCT02254239,Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT02254278,Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NCT02254551,Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT02254772,"TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma"
NCT02254785,Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
NCT02255097,Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
NCT02255461,"Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors"
NCT02256111,EXTEND Exercise Trial
NCT02256436,"A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)"
NCT02257138,Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
NCT02257424,"The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma"
NCT02257528,"Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer"
NCT02257541,BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
NCT02257567,A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
NCT02257619,Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
NCT02257736,An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02258451,Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
NCT02258464,Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
NCT02258607,Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
NCT02259010,A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
NCT02259114,"A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors"
NCT02259231,RTA 408 Capsules in Patients With Melanoma - REVEAL
NCT02259582,"A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer"
NCT02259621,"Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC"
NCT02259725,Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
NCT02260440,A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
NCT02260531,Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases
NCT02260661,"Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours"
NCT02261220,A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
NCT02261805,A Phase I/II Study of Ganetespib in Combination With Doxorubicin
NCT02262741,"A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer"
NCT02262910,Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer
NCT02263508,MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma
NCT02263898,Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
NCT02264613,Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors
NCT02264678,Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264990,Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers
NCT02265341,Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions
NCT02265510,"An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies"
NCT02265536,A Study of LY3022855 In Participants With Breast or Prostate Cancer
NCT02266147,Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
NCT02266745,A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors
NCT02267083,Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
NCT02267603,Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
NCT02268175,Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
NCT02268370,Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD)
NCT02268825,Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers
NCT02268851,A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
NCT02269085,A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
NCT02269293,"Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers"
NCT02269579,Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
NCT02269670,Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy
NCT02269943,Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
NCT02270372,Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
NCT02270463,SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
NCT02270788,Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
NCT02270814,"Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma"
NCT02271139,Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib
NCT02271906,The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting
NCT02272413,Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer
NCT02272686,Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
NCT02272790,"A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer."
NCT02272855,A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
NCT02272998,Ponatinib Hydrochloride in Treating Patients With Refractory Metastatic Cancers and Genetic Alterations
NCT02273102,Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA)
NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
NCT02273362,Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Undergoing Surgery
NCT02273375,Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT02273739,"Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation"
NCT02273752,"Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer"
NCT02273973,Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
NCT02274012,"Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer"
NCT02275039,p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
NCT02275533,Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
NCT02276443,Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy
NCT02277093,Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
NCT02277184,"Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma"
NCT02277197,Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT02277457,"Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations"
NCT02278120,"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer"
NCT02278133,Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
NCT02278185,Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
NCT02278783,"Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer"
NCT02278965,Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer
NCT02279394,Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma
NCT02279433,"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b"
NCT02279719,"A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma"
NCT02279862,Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive
NCT02281084,Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes
NCT02281279,"Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma"
NCT02281955,De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC
NCT02282020,Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.
NCT02282345,Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation
NCT02282358,Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
NCT02282371,Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
NCT02282917,Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
NCT02283177,A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
NCT02283320,A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
NCT02283359,Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
NCT02283658,"Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer"
NCT02284971,Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04)
NCT02285244,"Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation"
NCT02285439,MEK 162 for Children w/Progressive/Recurrent Cancer/Study for Children w/Low-Grade Gliomas/Other Ras/Raf/MAP Pathway Activated Tumors
NCT02285855,Metformin in Non Small Cell Lung Cancer (NSCLC)
NCT02285959,Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
NCT02286687,Phase II Study of BMN 673
NCT02286726,Phase II CPX-351 in Acute Myeloid Leukemia (AML)
NCT02286843,"Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?"
NCT02286921,"Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance"
NCT02287025,A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?
NCT02287233,A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)
NCT02287727,Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment
NCT02288507,Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
NCT02289144,Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
NCT02289209,Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
NCT02289222,Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
NCT02289690,Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
NCT02289833,"A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
NCT02289898,"Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma"
NCT02289950,A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer
NCT02290951,A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
NCT02291055,Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer
NCT02291913,Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
NCT02292173,Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
NCT02292225,IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi
NCT02292550,Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
NCT02292758,"Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer"
NCT02293005,Alisertib in Malignant Mesothelioma
NCT02293980,"A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma"
NCT02294006,Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs
NCT02296112,Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
NCT02296125,AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT02296242,Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
NCT02296684,Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
NCT02296801,A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
NCT02296918,ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL
NCT02297230,Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics
NCT02297698,Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
NCT02298153,A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT02298348,Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
NCT02298387,A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
NCT02298959,Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
NCT02299141,Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
NCT02299505,Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT02299518,Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02299635,A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
NCT02300545,Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
NCT02300610,Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
NCT02300935,Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
NCT02300987,"A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression"
NCT02301039,A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
NCT02301117,A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
NCT02301130,Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
NCT02301156,Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
NCT02301364,Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
NCT02301988,A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer
NCT02302339,A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma
NCT02302807,A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
NCT02302833,Cabozantinib for Malignant Pheochromocytoma
NCT02303028,Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours
NCT02303041,Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
NCT02303262,A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
NCT02303392,Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
NCT02303444,An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
NCT02303990,RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
NCT02304393,A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors
NCT02304419,A Study of Galunisertib on the Immune System in Participants With Cancer
NCT02304458,Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
NCT02305186,Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
NCT02305563,An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02305758,Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
NCT02306135,Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer
NCT02306161,Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02306291,"Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML"
NCT02306850,Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
NCT02307149,Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma
NCT02307240,"Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors"
NCT02307474,A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
NCT02308020,A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the Brain
NCT02308280,Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
NCT02308761,A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT02309177,"Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer"
NCT02309567,"Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?"
NCT02309580,Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
NCT02311361,Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
NCT02311582,MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
NCT02311920,Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
NCT02311933,"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer"
NCT02311998,Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)
NCT02312102,Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
NCT02312245,"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
NCT02312557,Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
NCT02312804,Ph Ib/BGJ398/Cervix and Other Solid Tumors
NCT02313012,Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
NCT02313272,Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
NCT02314052,"Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma"
NCT02314117,A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
NCT02314156,Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
NCT02314169,Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
NCT02314364,A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC
NCT02315066,Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
NCT02315326,"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)"
NCT02315430,"Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02315534,A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
NCT02315625,Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
NCT02315768,Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
NCT02316002,Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
NCT02316340,Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
NCT02316834,POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer
NCT02317016,"Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer"
NCT02317874,"PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery"
NCT02317991,Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
NCT02318277,A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
NCT02318329,"Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors"
NCT02318368,"A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label"
NCT02318394,A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
NCT02318771,"Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer"
NCT02318901,Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
NCT02319018,Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
NCT02319044,"Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck"
NCT02319369,"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies"
NCT02319824,NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
NCT02319837,Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02320058,A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204)
NCT02320305,MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
NCT02321293,A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC
NCT02321501,Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression
NCT02321540,A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
NCT02322281,"TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy"
NCT02322814,A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer
NCT02323113,"Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)"
NCT02323126,Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
NCT02323191,A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors
NCT02323230,A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
NCT02323607,Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
NCT02323880,Study of Selinexor in Pediatric Solid Tumors
NCT02323906,Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
NCT02324582,MK-3475/BCG in High Risk Superficial Bladder Cancer
NCT02324608,Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
NCT02324621,Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
NCT02325401,Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT02325557,ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
NCT02325739,Safety and Efficacy of FGF401 in Patients With Solid Malignancies
NCT02326844,"BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment"
NCT02326974,T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
NCT02327078,"A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers"
NCT02327169,A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies
NCT02328014,"ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies"
NCT02329847,Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
NCT02330562,Study of Marizomib With Bevacizumab in Bevacizumab-Na&#239;ve Subjects With WHO Grade IV Malignant Glioma
NCT02331251,Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
NCT02331368,Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma
NCT02332655,Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome
NCT02332668,"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)"
NCT02332889,Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
NCT02332902,Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
NCT02332980,A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma
NCT02333162,"Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant"
NCT02334319,Ganetespib Window of Opportunity Study in Head and Neck Cancers
NCT02334527,Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy
NCT02334735,A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence
NCT02335203,The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy
NCT02335411,A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
NCT02335424,Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
NCT02335814,First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
NCT02335918,A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
NCT02335944,Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.
NCT02336087,"Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer"
NCT02336165,Phase 2 Study of MEDI4736 in Patients With Glioblastoma
NCT02336451,A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
NCT02336815,Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies
NCT02336984,A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS
NCT02337309,SF1126 for Patients With Relapsed or Refractory Neuroblastoma
NCT02337491,Pembrolizumab +/- Bevacizumab for Recurrent GBM
NCT02337530,Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
NCT02337686,Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
NCT02337829,ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
NCT02337985,Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
NCT02339168,Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer
NCT02339324,Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
NCT02339558,Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
NCT02339571,Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT02339740,Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
NCT02340117,Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
NCT02340156,Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
NCT02340221,SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
NCT02340611,A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib
NCT02340780,Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
NCT02340975,"A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma"
NCT02341456,Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
NCT02341625,A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
NCT02342353,Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)
NCT02342379,TH-302 in Combination With Bevacizumab for Glioblastoma
NCT02342782,Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
NCT02343042,Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma
NCT02343120,Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
NCT02343172,Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
NCT02343406,ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma
NCT02343536,"A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma"
NCT02343549,LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer
NCT02343666,HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
NCT02343679,Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
NCT02343718,Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
NCT02343939,Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
NCT02343952,"Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC"
NCT02344810,"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer"
NCT02345265,"Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer"
NCT02345382,Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
NCT02345772,"Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer"
NCT02345824,Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma
NCT02346253,High-Dose Brachytherapy in Treating Patients With Prostate Cancer
NCT02346747,Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL)
NCT02346955,Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
NCT02348008,Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma
NCT02348216,A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)
NCT02348255,NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
NCT02348398,Phase II Study of Pazopanib and Topotecan in Cervical Cancer
NCT02348489,"SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction"
NCT02349139,"Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer"
NCT02349633,Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
NCT02349867,"Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients"
NCT02349958,Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
NCT02350673,A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors
NCT02350764,Evaluate the Mediators of Sensitivity and Resistance to Nivolumab in Patients With Advanced NSCLCs
NCT02351037,A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
NCT02351505,Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
NCT02351739,Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer
NCT02352025,S-equol in Women With Triple Negative Breast Cancer
NCT02352558,"A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies"
NCT02352844,"Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations"
NCT02352948,"A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer"
NCT02353715,"Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing"
NCT02353728,Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
NCT02354131,Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA)
NCT02354547,A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
NCT02354586,A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens
NCT02355431,INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
NCT02355535,Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies
NCT02356159,Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
NCT02357147,Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS)
NCT02357810,Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
NCT02357836,Neoadjuvant Itraconazole in Non-small Cell Lung Cancer
NCT02358031,A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
NCT02358187,A Vaccine Trial for Low Grade Gliomas
NCT02358200,Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
NCT02358863,Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA)
NCT02359019,Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy
NCT02359565,"Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas"
NCT02359851,Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
NCT02360059,Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer
NCT02360618,Metformin and Simvastatin Use in Bladder Cancer
NCT02362035,"ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)"
NCT02362048,ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
NCT02362594,Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
NCT02362997,Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL
NCT02363283,Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
NCT02364076,MK-3475 in Patients With Thymic Carcinoma
NCT02364609,Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
NCT02364999,A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
NCT02365597,An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer
NCT02365662,A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
NCT02365766,Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer
NCT02365818,Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure
NCT02366130,Phase II Trial of Ra-223 Dichloride and Hormonal Treatment
NCT02366143,TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
NCT02366312,"A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors"
NCT02366494,Micro RNAs to Predict Response to Androgen Deprivation Therapy
NCT02366728,DC Migration Study for Newly-Diagnosed GBM
NCT02366949,Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
NCT02367040,Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
NCT02367456,"A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients"
NCT02367781,A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer
NCT02367794,A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02367859,Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma
NCT02368301,Expanded Access Treatment Protocol CA204-143
NCT02368691,Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
NCT02368886,Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02368951,"Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)"
NCT02368990,T790M Mutation Positive 2nd Line STandard of cAre Registry
NCT02369016,Phase III Copanlisib in Rituximab-refractory iNHL
NCT02369029,"BAY1238097, First in Man"
NCT02369874,Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
NCT02370238,A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
NCT02371369,PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
NCT02372006,Phase I Trial of Afatinib in Pediatric Tumours
NCT02372227,"A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma"
NCT02372240,A Study of VLX1570 and Dexamethasone in Myeloma Patients
NCT02374099,Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
NCT02375555,"Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM"
NCT02375672,Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
NCT02376166,Metformin for Rising PSA Remote Trial
NCT02376699,Safety Study of SEA-CD40 in Cancer Patients
NCT02379247,BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
NCT02379390,Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB)
NCT02379416,Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
NCT02379520,"HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)"
NCT02379585,Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer
NCT02381080,Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
NCT02381236,G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
NCT02381314,Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer
NCT02381535,Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin
NCT02381548,Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
NCT02381886,A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02382406,Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC
NCT02382549,A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma
NCT02383212,Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
NCT02383433,Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
NCT02383927,Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations
NCT02384239,A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
NCT02384382,A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
NCT02384746,Phase I Study of the Combination of MLN9708 and Fulvestrant
NCT02384954,ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab
NCT02385669,A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
NCT02386111,A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT02386501,Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
NCT02386826,"INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients"
NCT02387125,"A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1"
NCT02387216,A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
NCT02387996,A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
NCT02388906,Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
NCT02389309,"A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors"
NCT02389751,A Study of Ganetespib in Combination With Chemoradiation
NCT02389764,Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC)
NCT02390427,Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
NCT02390752,PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
NCT02391116,Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02391480,A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
NCT02391727,"Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1)"
NCT02392507,A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
NCT02392572,ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS)
NCT02392611,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas"
NCT02392676,Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
NCT02392793,Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
NCT02393248,"Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies"
NCT02393625,Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
NCT02393690,Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
NCT02393755,Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02393794,Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT02394652,The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer
NCT02395172,Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
NCT02395601,A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
NCT02395627,Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification
NCT02395666,Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
NCT02396368,A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
NCT02397083,Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer
NCT02397720,A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia
NCT02399085,A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
NCT02399137,A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
NCT02399215,Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT02399371,Pembrolizumab in Treating Patients With Malignant Mesothelioma
NCT02399813,Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum
NCT02399943,A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
NCT02400242,Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
NCT02400255,Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
NCT02400281,Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
NCT02400385,A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
NCT02400476,A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
NCT02400814,MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
NCT02401048,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
NCT02401295,"ATRA, Celecoxib, and Itraconazole as Maintenance"
NCT02401347,Talazoparib Beyond BRCA (TBB) Trial
NCT02401542,A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
NCT02401815,A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST
NCT02402036,A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer
NCT02402348,"Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis"
NCT02402712,Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
NCT02402764,Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC
NCT02402920,Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer
NCT02403193,Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO)
NCT02403271,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
NCT02403310,A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
NCT02403505,Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms
NCT02403895,AZD2014 and Weekly Paclitaxel in Squamous NSCLC
NCT02404441,Phase I/II Study of PDR001 in Patients With Advanced Malignancies
NCT02404480,PTC596 in Patients With Advanced Solid Tumors
NCT02406508,Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
NCT02406521,Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases
NCT02406742,"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)"
NCT02407054,A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
NCT02407171,Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
NCT02407405,Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
NCT02407990,"Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors"
NCT02408042,Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
NCT02408861,Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors
NCT02409134,Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat
NCT02409342,A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02409355,A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer
NCT02410512,A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors
NCT02411448,A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC
NCT02411656,MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)
NCT02411786,A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF
NCT02412371,A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer
NCT02412462,Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
NCT02412475,Epigenetic Reprogramming in Relapse AML
NCT02412670,Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
NCT02412722,"Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies"
NCT02413827,A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
NCT02413853,Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
NCT02414139,Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy
NCT02414165,P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5)
NCT02414516,A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
NCT02414646,Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer
NCT02414724,Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT02415608,Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
NCT02415621,Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
NCT02415881,Phase I Panitumumab IRDye800 Optical Imaging Study
NCT02416908,Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
NCT02417701,TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer
NCT02417753,"AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites"
NCT02418000,A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation
NCT02419417,Study of BMS-986158 in Subjects With Select Advanced Solid Tumors
NCT02419495,Selinexor in Combination With Standard Chemotherapy
NCT02419560,Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
NCT02419755,Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
NCT02420613,Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG)
NCT02420652,Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy
NCT02420691,LEE011 in Neuroendocrine Tumors of Foregut Origin
NCT02420717,Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
NCT02420795,Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT02420821,A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
NCT02420860,Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT)
NCT02420912,"Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)"
NCT02421939,A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
NCT02422381,MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
NCT02422589,"A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors"
NCT02422615,Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.
NCT02422979,Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer
NCT02423057,Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
NCT02423343,"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma"
NCT02423525,Safety Study of Afatinib for Brain Cancer
NCT02423863,"In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol"
NCT02423902,A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
NCT02423915,Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
NCT02423954,Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
NCT02424617,A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
NCT02425306,Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
NCT02425683,Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
NCT02425891,A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer
NCT02426125,A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
NCT02426723,Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients
NCT02426892,Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
NCT02427451,"Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia"
NCT02427581,Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02427620,A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
NCT02428192,Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma
NCT02428270,A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer
NCT02428712,"A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors"
NCT02428855,Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
NCT02429193,Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P)
NCT02429375,Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT02429466,Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
NCT02429843,A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer
NCT02430480,Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
NCT02431169,Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
NCT02431208,A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM)
NCT02431260,"An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies"
NCT02431559,"A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated"
NCT02431676,Survivorship Promotion In Reducing IGF-1 Trial (SPIRIT)
NCT02432274,Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies
NCT02432326,A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
NCT02432560,Safety and Durability of Sirolimus for Treatment of LAM
NCT02432690,A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
NCT02432846,Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA)
NCT02432963,Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
NCT02434354,A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
NCT02435121,A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification
NCT02435433,A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)
NCT02435680,Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
NCT02435849,Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA)
NCT02436408,VISmodegib for ORbital and Periocular Basal Cell Carcinoma
NCT02436668,"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma"
NCT02436707,Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT02436993,Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
NCT02437071,Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
NCT02437136,Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
NCT02437318,Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
NCT02437370,Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
NCT02437812,"Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma"
NCT02438007,A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
NCT02438722,"S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer"
NCT02439450,A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
NCT02439723,Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients
NCT02440425,Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
NCT02440464,Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
NCT02441517,A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide
NCT02441686,"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma"
NCT02441946,"A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer"
NCT02442297,T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
NCT02442414,A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors
NCT02443077,Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT02443324,"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium"
NCT02443337,A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
NCT02443883,A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
NCT02444741,MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC)
NCT02444793,A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
NCT02445248,Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET)
NCT02446236,"Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)"
NCT02446405,Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446431,Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
NCT02446444,"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer"
NCT02446457,Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
NCT02446600,"Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02446704,Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
NCT02447003,Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
NCT02448251,"Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer"
NCT02448303,Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer
NCT02448589,An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel
NCT02448771,A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
NCT02448810,Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
NCT02449239,Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
NCT02449681,Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS
NCT02450175,"Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls"
NCT02450331,"IMvigor 010 Study: Anti-Programmed Death-Ligand 1 (PD-L1) Antibody MPDL3280A Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy"
NCT02450539,A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
NCT02450591,Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
NCT02451423,Study of MPDL3280A in Bladder Cancer
NCT02451553,"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer"
NCT02451852,AZD9291 US Expanded Access Program
NCT02451865,"Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer"
NCT02451930,A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
NCT02451943,A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
NCT02451982,Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer
NCT02452008,Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT02452268,A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
NCT02452281,Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
NCT02452424,A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
NCT02452463,Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
NCT02452775,Autologous OC-L Vaccine and Ovarian Cancer
NCT02452970,RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC)
NCT02453282,Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).
NCT02453594,Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
NCT02453620,"Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer"
NCT02454010,A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
NCT02454179,Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma
NCT02454270,A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies
NCT02454842,"Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC"
NCT02454933,Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
NCT02454972,Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
NCT02455297,Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT02456701,Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
NCT02456857,"Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy"
NCT02456883,"Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors"
NCT02457351,Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
NCT02457793,"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors"
NCT02457910,Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
NCT02458339,Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors
NCT02458638,An Open Label Study of MPDL3280A in Advanced Solid Tumors
NCT02459119,Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
NCT02459301,"Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin"
NCT02460198,Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
NCT02460224,Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
NCT02460367,Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
NCT02460991,A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
NCT02462252,"Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome"
NCT02463032,Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
NCT02463799,Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
NCT02463994,A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
NCT02464228,Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT02464657,Nivolumab in Acute Myeloid Leukemia (AML)
NCT02464761,Photodynamic Therapy for the Treatment of Vertebral Metastases
NCT02465060,NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
NCT02466009,Regorafenib in Metastatic Colorectal Cancer
NCT02466568,Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
NCT02466802,Study of Regorafenib and Sildenafil for Advanced Solid Tumors
NCT02467270,Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses
NCT02467361,A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
NCT02468661,"A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification"
NCT02469415,Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
NCT02469701,BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease
NCT02470091,Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
NCT02470585,"Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02470741,Pilot of Letrozole for Uterine Myomas (PLUM)
NCT02471716,Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
NCT02471846,A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
NCT02471911,KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT02472145,An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
NCT02472275,"PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer"
NCT02472353,Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer
NCT02472392,Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma
NCT02472977,Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
NCT02473497,Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients
NCT02473731,A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
NCT02474173,HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
NCT02474355,Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
NCT02475213,Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer
NCT02475382,Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169)
NCT02475681,"Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL"
NCT02476786,Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT02476955,Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel
NCT02476968,To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer
NCT02477696,Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia
NCT02477826,"An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)"
NCT02477878,Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
NCT02478164,Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
NCT02478320,Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors
NCT02479178,"A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)"
NCT02481050,Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
NCT02481154,"Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation"
NCT02481830,Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer
NCT02482168,Study of the CD40 Agonistic Monoclonal Antibody APX005M
NCT02482441,"A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10"
NCT02483247,A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
NCT02483858,Study of Oral PQR309 in Patients With Advanced Solid Tumors
NCT02484261,Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children
NCT02484404,Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer
NCT02484430,TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
NCT02485535,Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
NCT02485652,Phase II Trial of HM61713 (BI 1482694) for the Treatment of >2nd Line T790M Mutation Positive Adenocarcinoma of the Lung (NSCLC)
NCT02485990,"Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)"
NCT02486718,Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer
NCT02487095,"Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer"
NCT02487459,Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
NCT02487979,Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
NCT02488408,Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML
NCT02488759,A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)
NCT02489006,"A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer"
NCT02489058,A Study of Long-Term Responders on Olaparib (OLALA)
NCT02489123,Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT02489318,A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC
NCT02489357,"Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer"
NCT02489448,Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
NCT02489903,"RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens"
NCT02490878,Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
NCT02490930,A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
NCT02491099,A Phase II Evaluation of Afatinib
NCT02491411,Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
NCT02492711,Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
NCT02492737,Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
NCT02493361,Trial of pIL-12/MK-3475 in Metastatic Melanoma
NCT02493751,A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer
NCT02494570,A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa
NCT02494583,Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
NCT02494713,Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
NCT02494882,Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
NCT02494921,LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
NCT02495103,Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
NCT02495415,Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas
NCT02495636,"Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer"
NCT02496208,Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
NCT02496585,Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
NCT02496663,EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
NCT02497638,LIpitor and biGuanide to Androgen Delay Trial
NCT02498600,"Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
NCT02498613,Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02498665,A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
NCT02499120,Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
NCT02499328,Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck
NCT02499770,G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
NCT02499835,"Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer"
NCT02499861,Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies
NCT02499952,Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
NCT02500043,Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
NCT02500121,Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer
NCT02500199,Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy
NCT02500407,A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT02500576,"MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)"
NCT02500797,Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma
NCT02500901,Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)
NCT02501096,Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
NCT02501473,Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma
NCT02501902,Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
NCT02502266,"Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02502708,"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors"
NCT02503358,Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT02503709,Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02503722,TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
NCT02503774,MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
NCT02504489,Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion
NCT02504892,Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
NCT02506114,Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
NCT02506153,High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506517,A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene
NCT02506959,Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma
NCT02507570,Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis
NCT02507583,Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
NCT02508038, Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa
NCT02508077,FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
NCT02508246,"AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck"
NCT02508467,A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma
NCT02508532,Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
NCT02508636,Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate
NCT02508870,"A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes"
NCT02510950,Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
NCT02511106,"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy"
NCT02511132,Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma
NCT02511184,Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients
NCT02511405,"A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)"
NCT02511795,AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors
NCT02512172,A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
NCT02512926,Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
NCT02513394,PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS)
NCT02513472,Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
NCT02513563,AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
NCT02513667,Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
NCT02514083,A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT02514174,Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
NCT02514382,"Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma"
NCT02514447,Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
NCT02514551,A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
NCT02514824,MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
NCT02516241,Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516813,"Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy"
NCT02517398,MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
NCT02518113,A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
NCT02518555,"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"
NCT02518750,Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
NCT02518958,"A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab"
NCT02519322,Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
NCT02519348,"A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma"
NCT02520011,Alvocidib Biomarker-driven Phase 2 AML Study
NCT02520063,"Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer"
NCT02520115,Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
NCT02520141,Ramucirumab for Advanced Pre-treated Biliary Cancers
NCT02520154,Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
NCT02520752,A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
NCT02520778,EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
NCT02520791,Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
NCT02521051,"Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer"
NCT02521090,EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
NCT02521493,Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521870,A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma
NCT02522715,"Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer"
NCT02523014,A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas
NCT02523469,"ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer"
NCT02524119,LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001)
NCT02525692,Oral ONC201 in Adult Recurrent Glioblastoma
NCT02525757,MPDL3280A With Chemoradiation for Lung Cancer
NCT02526017,Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers
NCT02527174,A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC)
NCT02527434,Study of Tremelimumab in Patients With Advanced Solid Tumors
NCT02528357,GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT02528643,A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma
NCT02528877,"Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis"
NCT02529072,Nivolumab With DC Vaccines for Recurrent Brain Tumors
NCT02529553,A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
NCT02530125,Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission
NCT02530437,"A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction"
NCT02530463,Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)
NCT02530476,"Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia"
NCT02530489,Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A
NCT02530502,Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
NCT02530619,Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
NCT02531308,Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
NCT02531516,An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy
NCT02531932,Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
NCT02532010,Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
NCT02532114,"Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer"
NCT02532192,"A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma"
NCT02532231,Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse
NCT02532257,Study of Ibrutinib in Combination With Rituximab and Lenalidomide
NCT02533115,EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
NCT02535078,Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma
NCT02535247,Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma
NCT02535286,Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL
NCT02535338,Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
NCT02535533,SLM + Axitinib for Clear Cell RCC
NCT02535806,Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
NCT02536339,Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
NCT02536495,Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
NCT02536794,MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
NCT02537223,Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer
NCT02537418,Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens
NCT02537444,ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191)
NCT02537561,Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
NCT02537613,A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02538484,Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
NCT02538510,Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
NCT02538614,Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
NCT02538627,Phase 1 Combination Study of MM-151 and MM-121
NCT02538666,"A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)"
NCT02538926,"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma"
NCT02539459,Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus
NCT02540161,Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
NCT02540291,Study of E7046 in Subjects With Selected Advanced Malignancies
NCT02540330,PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy
NCT02540356,Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
NCT02540876,Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
NCT02541565,Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma
NCT02541604,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors"
NCT02541903,Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma
NCT02542124,NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
NCT02542293,Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).
NCT02543255,Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)
NCT02543645,A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT02544633,Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET
NCT02545283,A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02545504,GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02546531,Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
NCT02546661,"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer"
NCT02546986,Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT02547675,Rociletinib (CO-1686) USA Expanded Access Program
NCT02548962,Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
NCT02549209,Pembro/Carbo/Taxol in Endometrial Cancer
NCT02549651,MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023)
NCT02549937,"A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors"
NCT02549989,Study of LY3023414 for the Treatment of Recurrent
NCT02550743,"BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study"
NCT02551055,"MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma"
NCT02551159,Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN
NCT02551185,ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
NCT02551718,High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
NCT02553460,Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
NCT02553642,Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
NCT02553941,Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
NCT02554812,A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
NCT02555189,"Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression"
NCT02555644,A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer
NCT02555657,Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
NCT02555878,A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
NCT02556463,A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors
NCT02556931,"Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies"
NCT02557321,PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
NCT02557516,Combination Study of IPH2201 With Ibrutinib in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia
NCT02558140,A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT02558894,Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
NCT02559024,Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
NCT02559492,INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors
NCT02559674,ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel
NCT02559687,Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
NCT02559778,Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02560012,Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
NCT02560025,Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
NCT02560779,Trial of TRC105 and Sorafenib in Patients With HCC
NCT02561455,Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
NCT02561832,"A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer"
NCT02561988,Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
NCT02562443,Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)
NCT02562755,Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
NCT02562898,Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NCT02563002,Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
NCT02563548,Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab
NCT02563925,Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
NCT02564198,A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
NCT02564263,Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
NCT02564536,Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
NCT02564614,"A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)"
NCT02564900,Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
NCT02565758,"ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors"
NCT02565901,"Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer"
NCT02565992,Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma
NCT02566772,Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer
NCT02567396,Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
NCT02567409,Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer
NCT02567422,"VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma"
NCT02567435,Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567656,Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
NCT02568046,Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
NCT02568267,"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements  (STARTRK-2)"
NCT02568449,Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
NCT02568943,"An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma"
NCT02569242,Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
NCT02569320,HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
NCT02569476,BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies
NCT02569801,A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy
NCT02570308,A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
NCT02570542,Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT02570711,Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer
NCT02571036,"A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies"
NCT02571530,Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
NCT02571725,PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
NCT02572167,A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
NCT02572453,"AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma"
NCT02572687,A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
NCT02573220,Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
NCT02573324,A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
NCT02573363,Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
NCT02573493,Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
NCT02574078,A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370)
NCT02574533,Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma
NCT02574663,TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
NCT02574728,Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
NCT02575222,Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
NCT02575300,Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
NCT02575339,MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
NCT02575404,GR-MD-02 Plus Pembrolizumab in Melanoma Patients
NCT02575508,Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
NCT02575781,A Study of SAR428926 in Patients With Advanced Solid Tumors
NCT02575807,"Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer"
NCT02576275,A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
NCT02576301,Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
NCT02576431,Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
NCT02576444,OLAParib COmbinations
NCT02576496,"Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies"
NCT02576509,A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT02576574,Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)
NCT02576665,"A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)"
NCT02576977,Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
NCT02576990,Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170)
NCT02577406,An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY)
NCT02578680,Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
NCT02578797,A JNJ-56021927 (ARN-509) QT/QTc Study
NCT02579226,"A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors"
NCT02579811,Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
NCT02579824,DS-3032b for Relapsed and/or Refractory (RR) Myeloma
NCT02579863,Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
NCT02580448,"A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer"
NCT02580708,A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT02581059,Efficacy of Ginseng for Patients on Regorafenib
NCT02581137,Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
NCT02581215,Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
NCT02581631,A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)
NCT02581787,SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
NCT02581930,Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma
NCT02581943,Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
NCT02581982,Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
NCT02582749,Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
NCT02583477,Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
NCT02583893,Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
NCT02584309,Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
NCT02584634,"Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)"
NCT02584647,Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2)
NCT02584829,Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
NCT02584933,Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
NCT02585973,Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
NCT02586207,Pembrolizumab in Combination With CRT for LA-SCCHN
NCT02586675,TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
NCT02586857,"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)"
NCT02586987,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours"
NCT02587598,Study of INCB053914 in Subjects With Advanced Malignancies
NCT02587962,Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
NCT02588105,Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
NCT02588261,A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
NCT02589145,Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
NCT02589522,VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
NCT02589717,An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
NCT02591615,Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
NCT02591654,MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma
NCT02592356,Tyrosine Kinase Inhibitors (TKI) and Body Composition
NCT02592551,MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
NCT02593175,"Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy"
NCT02593708,"Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+"
NCT02594072,Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT)
NCT02595866,"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms"
NCT02595892,"Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
NCT02595905,Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer
NCT02595918,Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer
NCT02595931,VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02595944,Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL)
NCT02596035,A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374)
NCT02596971,Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma
NCT02597036,A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
NCT02598427,Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer
NCT02598557,Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
NCT02598661,Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598960,A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors
NCT02599324,A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
NCT02599363,A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
NCT02599402,Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
NCT02599454,Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
NCT02599649,Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
NCT02599714,Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR)
NCT02599779,A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
NCT02600897,"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)"
NCT02601014,Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
NCT02601209,Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
NCT02601313,A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
NCT02601937,A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
NCT02601950,"A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma"
NCT02602327,Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
NCT02603419,Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
NCT02603432,A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
NCT02603887,Pembrolizumab for Smoldering Multiple Myeloma (SMM)
NCT02604511,"Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing"
NCT02605044,Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer
NCT02605083,A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
NCT02605356,Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
NCT02605486,Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
NCT02605694,Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
NCT02605746,Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis
NCT02605863,Enzalutamide for Bladder Cancer Chemoprevention
NCT02605915,Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer
NCT02605967,Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT02606123,Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02606305,"Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer"
NCT02606461,KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL)
NCT02607124,Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
NCT02607228,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer"
NCT02607553,Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
NCT02607813,Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
NCT02608125,A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors
NCT02608216,[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
NCT02608229,BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
NCT02608268,Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
NCT02608385,Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors
NCT02608684,A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
NCT02609503,Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
NCT02609984,Trial of CMB305 and Atezolizumab in Patients With Sarcoma
NCT02610075,Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.
NCT02610361,Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
NCT02610777,"An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)"
NCT02611063,Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant
NCT02611323,"A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)"
NCT02611908,Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
NCT02611960,"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)"
NCT02612194,LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
NCT02612285,Study of SNX-5422 in TP53 Null Cancers
NCT02612311,Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02612779,A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide
NCT02613416,Denosumab and Breast Imaging
NCT02613598,Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
NCT02613650,A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers
NCT02614066,A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3)
NCT02614456,Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors
NCT02614508,Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT02614794,Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT02614859,Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
NCT02616185,A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
NCT02616211,An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
NCT02616393,"Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases"
NCT02616640,A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
NCT02617277,"Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours"
NCT02617589,"Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)"
NCT02617849,Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
NCT02619253,Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
NCT02619669,Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer
NCT02619864,mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
NCT02620423,Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
NCT02620800,"Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer"
NCT02620839,Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
NCT02620865,Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
NCT02621021,A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
NCT02621151,"Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder"
NCT02621398,"Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer"
NCT02621957,Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential
NCT02624258,"Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma"
NCT02624388,Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
NCT02624570,Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.
NCT02624700,Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
NCT02624986,A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
NCT02625480,A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4)
NCT02625610,Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100)
NCT02625623,Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
NCT02625857,"Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer"
NCT02625961,Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
NCT02626000,Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02626130,Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC)
NCT02626234,A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
NCT02626338,Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML
NCT02626364,Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
NCT02626455,Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
NCT02626507,Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
NCT02627274,"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors"
NCT02627430,"Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer"
NCT02627443,"Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
NCT02627963,A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
NCT02628067,Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT02628574,Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors
NCT02628704,"Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma"
NCT02629809,"First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)"
NCT02630186,A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
NCT02630420,Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
NCT02630693,"Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer"
NCT02630823,MK-3475 Immunotherapy in Endometrial Carcinoma
NCT02631044,Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
NCT02631577,A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT02631590,Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
NCT02631733,Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
NCT02631746,Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
NCT02631876,"PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer"
NCT02632045,Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer
NCT02632071,Phase I of ACY-1215 + Nab-paclitaxel in Breast Cancer
NCT02632344,"Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement"
NCT02632409,A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma
NCT02632448,A Study of LY2880070 in Patients With Advanced or Metastatic Cancer
NCT02632708,Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
NCT02632721,A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
NCT02633059,"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma"
NCT02634827,Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation
NCT02635061,Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
NCT02635074,"Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia"
NCT02635360,Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
NCT02636036,Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors
NCT02636322,"A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma"
NCT02636582,Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
NCT02636725,Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
NCT02637375,A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
NCT02637531,"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549"
NCT02637687,Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors
NCT02638090,Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
NCT02638909,Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies
NCT02639026,"Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers"
NCT02639065,A Study of Durvalumab (MEDI4736) in Esophageal Cancer
NCT02639091,Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
NCT02639117,Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
NCT02639182,A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
NCT02639234,Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer
NCT02639546,iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
NCT02639559,Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
NCT02639910,Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)
NCT02640209,Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
NCT02640508,Eribulin and Lenvatinib in Advanced Solid Tumors
NCT02640833,"A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor"
NCT02641093,Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
NCT02642016,A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors
NCT02642042,Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
NCT02642094,Aging Mammary Stem Cells and Breast Cancer Prevention
NCT02642809,Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers
NCT02642913,Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
NCT02642939,Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
NCT02642965,"Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia"
NCT02643303,"A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers"
NCT02643550,Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02643667,A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
NCT02644122,SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
NCT02644369,Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
NCT02644460,Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors
NCT02644967,A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma
NCT02646319,Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
NCT02646748,Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
NCT02648282,"Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer"
NCT02648477,Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
NCT02648490,"An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers"
NCT02648633,Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
NCT02648711,Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors
NCT02648724,Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
NCT02648997,A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma
NCT02649387,Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT)
NCT02649530,"An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma"
NCT02649673,LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
NCT02649686,Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
NCT02649764,LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
NCT02649790,"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma"
NCT02650401,Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors
NCT02650635,"TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors"
NCT02650713,"A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors"
NCT02650752,Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
NCT02650804,BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients
NCT02650999,Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas
NCT02651415,Phase II Study of Perindopril and Regorafenib in mCRC
NCT02651610,Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
NCT02651662,Study of REGN2810 and REGN1979 in Patients With Lymphoma
NCT02651727,"Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects"
NCT02652455,"Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma"
NCT02652468,TCR-alpha/beta and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
NCT02652871,"A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia"
NCT02653196,A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
NCT02653612,Intraoperative Imaging of Pulmonary Adenocarcinoma
NCT02654119,"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery"
NCT02654132,Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma
NCT02654587,Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1)
NCT02654639,Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
NCT02654990,Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
NCT02655016,A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655458,Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma
NCT02655601,"Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001"
NCT02655822,Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
NCT02656303,An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
NCT02656706,BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial
NCT02656849,"BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors"
NCT02657005,TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
NCT02657343,"An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer."
NCT02657369,A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
NCT02657434,A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
NCT02657486,BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02657551,A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
NCT02657889,Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162)
NCT02657928,"Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer"
NCT02658019,Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
NCT02658084,Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
NCT02658097,"A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC"
NCT02658214,Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
NCT02658279,Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
NCT02658396,GO-203-2C + Bortezomib For Relapsed Or Refractory MM
NCT02658890,"Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers"
NCT02658929,Study of bb2121 in Multiple Myeloma
NCT02659020,A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
NCT02659059,Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568)
NCT02659241,A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer
NCT02659514,Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer
NCT02659540,A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma
NCT02661815,"A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer"
NCT02662296,"Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant"
NCT02663271,TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
NCT02663518,A Trial of TTI-621 for Patients With Hematologic Malignancies
NCT02663908,A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
NCT02664077,A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO)
NCT02664181,Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE)
NCT02664961,Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
NCT02665143,A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
NCT02665416,"Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors"
NCT02665650,Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02666105,Exemestane in Post-Menopausal Women With NSCLC
NCT02666209,Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
NCT02666950,WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02667587,"Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)."
NCT02667873,A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
NCT02667886,Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
NCT02668653,Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML
NCT02668666,Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
NCT02668770,Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
NCT02669173,Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
NCT02669511,PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
NCT02669914,MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
NCT02670044,A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
NCT02671955,"A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer"
NCT02672475,Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
NCT02672917,Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
NCT02673333,Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
NCT02673398,Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer
NCT02673736,A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
NCT02674061,Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
NCT02674555,"A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors"
NCT02674568,Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
NCT02674750,Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL
NCT02675231,"A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer"
NCT02675829,Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
NCT02676323,Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT02676986,"Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)"
NCT02677038,Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer
NCT02677116,A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
NCT02677896,A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT02677922,A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT02677948,Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT02678572,Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
NCT02679131,"To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment."
NCT02680184,Clinical Study of CMP-001 in Combination With Pembrolizumab
NCT02680795,"To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes"
NCT02680951,Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
NCT02681237,A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
NCT02681302,Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001)
NCT02681549,Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
NCT02684006,A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
NCT02684032,A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
NCT02684162,SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
NCT02684227,Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer
NCT02684253,"Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)"
NCT02684292,Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
NCT02684461,Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
NCT02684617,Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies  (MK-3475-155) (KEYNOTE-155)
NCT02685267,Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza)
NCT02685397,Management of Castration-Resistant Prostate Cancer With Oligometastases
NCT02685826,A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma
NCT02686164,Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
NCT02687009,A Study of Niclosamide in Patients With Resectable Colon Cancer
NCT02687230,Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1
NCT02688088,A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
NCT02688608,Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
NCT02688712,ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
NCT02689284,"Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer"
NCT02689336,Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
NCT02689427,Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)
NCT02689440,Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib
NCT02689921,NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT)
NCT02690558,Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
NCT02690948,Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
NCT02692755,Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer (PALINA)
NCT02693535,TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02694809,Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery
NCT02694822,"AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers"
NCT02695290,Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
NCT02696993,Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer
NCT02697591,"An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors"
NCT02698176,A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)
NCT02698189,A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005)
NCT02699723,Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
NCT02700022,A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
NCT02700841,Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation
NCT02701400,Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
NCT02701673,Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
NCT02702388,"Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile"
NCT02702401,Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
NCT02702414,Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)
NCT02702492,PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA)
NCT02702960,"Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)"
NCT02703272,A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
NCT02703571,Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
NCT02703623,A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)
NCT02703714,Pembrolizumab and GM-CSF in Biliary Cancer
NCT02703779,Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
NCT02705105,Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
NCT02705339,Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
NCT02705469,A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02705482,A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
NCT02705963,A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors
NCT02706353,APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
NCT02706405,JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT02706626,Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors
NCT02706691,"Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer"
NCT02707666,A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
NCT02708641,A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML
NCT02708680,Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
NCT02709083,"Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia"
NCT02709889,Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
NCT02710396,Genetic Predictors of Benefit to Pembrolizumab
NCT02711137,"A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies"
NCT02711553,A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711956,A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02712723,"Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer"
NCT02712905,"An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies"
NCT02713373,Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
NCT02713386,"Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02713529,Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
NCT02713828,"Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung"
NCT02713867,"A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384)"
NCT02714218,"A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma"
NCT02715531,A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
NCT02716038,"Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC"
NCT02716077,Early FDG PET in Melanoma
NCT02716116,A Trial of AP32788 in Non-Small Cell Lung Cancer
NCT02716805,"Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant"
NCT02716948,Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
NCT02716974,A Study of Definitive Therapy to Treat Prostate Cancer
NCT02717156,Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs
NCT02717455,Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
NCT02717611,A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717624,A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma
NCT02718066,"Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer"
NCT02718300,A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
NCT02718417,Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
NCT02718833,"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma"
NCT02718911,A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
NCT02719015,Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
NCT02719574,Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation
NCT02719613,Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
NCT02720068,Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001)
NCT02720185,The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
NCT02720484,Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
NCT02720510,"A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)"
NCT02721433,4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA)
NCT02721459,XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma
NCT02721732,Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
NCT02721875,Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
NCT02721979,ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance
NCT02722668,UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep
NCT02722941,Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
NCT02722954,A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy
NCT02723006,"Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma"
NCT02723435,Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant
NCT02723864,"Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors"
NCT02723955,Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)
NCT02723994,A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
NCT02724020,MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
NCT02724878,Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
NCT02725268,"Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer"
NCT02725489,Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Breast Cancer
NCT02725541,Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
NCT02726399,Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer
NCT02726581,"Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma"
NCT02726997,Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer
NCT02728050,"Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome"
NCT02728258,Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT02728700,Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
NCT02728830,A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
NCT02729194,Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
NCT02729298,First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
NCT02729701,Pilot Study of the Effect of Duavee on Benign Breast Tissue Proliferation
NCT02729896,"A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)"
NCT02729961,Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
NCT02730130,Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
NCT02730195,Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
NCT02730247,Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT02730546,"Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery"
NCT02731729,Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
NCT02731742,Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)
NCT02732119,Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1)
NCT02732938,Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i)
NCT02733042,"A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)"
NCT02733250,Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001)
NCT02734004,A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)
NCT02734160,A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
NCT02734290,Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
NCT02734615,Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
NCT02735083,A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19
NCT02735356,Topical Itraconazole in Treating Patients With Basal Cell Cancer
NCT02735980,A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer
NCT02736123,Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
NCT02736435,Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound
NCT02736617,Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
NCT02737046,Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
NCT02737072,A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
NCT02737475,Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors
NCT02737501,ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients
NCT02737787,A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
NCT02738866,Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
NCT02740270,Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
NCT02740920,Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker
NCT02740985,A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies
NCT02741570,Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02742090,Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
NCT02743078,Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
NCT02743494,Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)
NCT02743546,"Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma"
NCT02743611,Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms
NCT02743637,A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (SDX-0101)
NCT02743819,Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
NCT02744287,Prostate Stem Cell Antigen (PSCA)-Specific CAR T Cells In Subjects With Non-Resectable Pancreatic Cancer
NCT02744612,Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT02745769,A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
NCT02746081,Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors
NCT02746328,Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
NCT02746952,Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM)
NCT02747004,A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1)
NCT02747537,Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
NCT02747797,"Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations"
NCT02748135,A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
NCT02748564,Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
NCT02748889,Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer
NCT02749513,Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients
NCT02749903,Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
NCT02750215,A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
NCT02750358,Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
NCT02750514,A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer
NCT02752035,"A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy"
NCT02752074,A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
NCT02752685,Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
NCT02753127,A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C)
NCT02753309,A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
NCT02753686,Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)
NCT02754141,A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers
NCT02754362,A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NCT02754726,Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754856,Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.
NCT02755272,A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT02755597,A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
NCT02756247,A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
NCT02756364,MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
NCT02756572,Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT02756611,A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Are Refractory or Intolerant to B-cell Receptor Inhibitors
NCT02756897,Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT02756962,Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
NCT02757326,ABC294640 in Refractory / Relapsed Multiple Myeloma
NCT02757391,T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies
NCT02758132,"Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases"
NCT02758717,Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
NCT02759016,"Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib"
NCT02759575,A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
NCT02759835,"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib"
NCT02760030,Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT02760485,A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02760498,Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
NCT02760797,A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
NCT02761057,"Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer"
NCT02761694,"Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null"
NCT02762006,Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
NCT02762513,Expansion Trial for Axitinib In Head And Neck Cancer
NCT02763384,BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
NCT02763579,A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133)
NCT02764333,TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
NCT02764541,Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
NCT02764593,Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
NCT02766478,Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer
NCT02766582,Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
NCT02766699,"A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)"
NCT02767804,eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
NCT02767934,Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
NCT02768363,Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
NCT02768389,Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
NCT02768558,Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
NCT02768701,Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
NCT02768766,Intermittent Selumetinib for Uveal Melanoma
NCT02768792,High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML
NCT02769520,"Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck"
NCT02769962,"Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer"
NCT02770014,Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
NCT02770391,ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer
NCT02771197,Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
NCT02771626,Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors
NCT02772588,AASUR in High Risk Prostate Cancer
NCT02774421,Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
NCT02774681,Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis
NCT02775292,"Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1"
NCT02775435,A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
NCT02775812,"Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma"
NCT02775851,Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
NCT02775903,An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)
NCT02776917,"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer"
NCT02777385,Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
NCT02778685,"Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib"
NCT02779283,Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02779751,A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779777,"Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes"
NCT02780011,Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
NCT02780024,"Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM"
NCT02780128,Next Generation Personalized Neuroblastoma Therapy
NCT02780310,Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
NCT02780609,Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
NCT02780700,Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
NCT02780713,A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK)
NCT02780804,Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02781506,Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer
NCT02782403,"Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases"
NCT02782546,Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
NCT02783599,A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
NCT02783625,Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
NCT02784158,An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
NCT02784171,Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
NCT02784483,"Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma"
NCT02784795,A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
NCT02785068,Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
NCT02785250,Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer
NCT02785913,Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
NCT02785939,Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
NCT02785952,Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
NCT02786485,Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
NCT02787005,Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199)
NCT02787369,ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
NCT02788201,Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
NCT02788279,A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma
NCT02788708,Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
NCT02788773,Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
NCT02788981,"A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer"
NCT02789345,A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
NCT02789657,BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
NCT02790515,Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
NCT02791334,A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT)
NCT02791594,Imaging FDG Flare in Melanoma
NCT02791919,"Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia"
NCT02792114,T-Cell Therapy for Advanced Breast Cancer
NCT02792192,Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants
NCT02792465,A Study of Investigational Drug CFI-402257 in Patients With Advanced Cancers
NCT02792725,Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
NCT02793219,Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
NCT02793466,Durvalumab in Pediatric and Adolescent Patients
NCT02793544,HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
NCT02793583,Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL)
NCT02793765,Docetaxel Followed by Provenge in Metastatic Prostate Cancer
NCT02794571,Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
NCT02794883,Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
NCT02795156,Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
NCT02795429,Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
NCT02795819,Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
NCT02795858,"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors"
NCT02796352,A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
NCT02796898,"Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer"
NCT02798406,Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)
NCT02799095,A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors
NCT02799602,ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS)
NCT02799745,A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT)
NCT02800486,"Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA"
NCT02801097,"A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer  (PAYLOAD) (PAYLOAD)"
NCT02801578,A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT02802163,"Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat"
NCT02803203,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
NCT02805660,Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
NCT02807272,Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML)
NCT02807454,A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)
NCT02807636,The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy
NCT02807805,"Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer"
NCT02807844,Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
NCT02808143,Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
NCT02808650,Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02810457,Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA)
NCT02811497,Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)
NCT02811809,Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer
NCT02811861,Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02812056,Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
NCT02812420,"Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy"
NCT02812524,Ipilimumab for Head and Neck Cancer Patients
NCT02812667,Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT02812693,Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
NCT02812875,"A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas"
NCT02814669,Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
NCT02815059,"Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone"
NCT02815397,DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
NCT02815592,Trial of BMS-986012 in Combination With Platinum and Etoposide
NCT02815995,Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
NCT02816021,Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
NCT02818023,Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma
NCT02818920,Neoadjuvant Pembrolizumab
NCT02819518,Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
NCT02819804,Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT02819999,A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer
NCT02820961,Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
NCT02821754,A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
NCT02823405,Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA)
NCT02823574,Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02823990,TG4010 and Nivolumab in Patients With Lung Cancer
NCT02824029,Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02824042,Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
NCT02824575,Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
NCT02826161,"A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)"
NCT02826434,Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
NCT02826486,Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT)
NCT02827838,Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
NCT02827877,Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer
NCT02827968,Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
NCT02828124,A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer
NCT02829723,Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
NCT02829840,"Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)"
NCT02829918,Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
NCT02829931,Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas
NCT02830594,"Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer"
NCT02831179,"Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor"
NCT02831257,AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
NCT02831491,A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
NCT02831686,"A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma"
NCT02831933,Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN)
NCT02833233,A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
NCT02833506,"Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02833610,A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency
NCT02833701,Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
NCT02833883,"Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer"
NCT02834013,Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834052,Pembrolizumab + Poly-ICLC in MRP Colon Cancer
NCT02834247,A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
NCT02834403,L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
NCT02834975,"Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC)."
NCT02835729,A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02835833,Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
NCT02837029,Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
NCT02837042,Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
NCT02837263,PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
NCT02837991,"A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma"
NCT02839681,Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
NCT02839694,Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
NCT02839707,"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02839720,Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma
NCT02840409,Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
NCT02840994,A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer
NCT02841748,"A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study"
NCT02842125,Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Solid Tumors
NCT02843074,"Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients"
NCT02844439,Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
NCT02844816,Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT02845297,Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients
NCT02845323,Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02846376,Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)
NCT02846623,Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL)
NCT02846766,Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
NCT02846792,"Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer"
NCT02846935,p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
NCT02846987,Study of Abemaciclib in Dedifferentiated Liposarcoma
NCT02847000,p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
NCT02847429,Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
NCT02847559,Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT02848651,A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST]
NCT02849496,Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer
NCT02849990,"Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery"
NCT02852655,"A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma"
NCT02853305,Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
NCT02853318,"Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT02853331,Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
NCT02853344,Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
NCT02853604,Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV)
NCT02854436,An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
NCT02855086,Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
NCT02855125,A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1
NCT02855944,"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients"
NCT02856568,"Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma"
NCT02857270,A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
NCT02857426,A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647)
NCT02858310,E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers
NCT02858869,Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
NCT02859324,A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
NCT02859454,Avelumab for People With Recurrent Respiratory Papillomatosis
NCT02860000,"Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer"
NCT02860286,Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
NCT02860546,A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
NCT02860676,Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
NCT02860780,A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
NCT02861040,Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02861573,Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
NCT02861898,Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
NCT02862275,Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
NCT02863991,Oral ONC201 in Relapsed/Refractory Multiple Myeloma
NCT02864251,"A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)"
NCT02864316,Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
NCT02864381,GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02864992,Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations
NCT02865811,"Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer"
NCT02867592,"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors"
NCT02867618,Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
NCT02868632,"Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer"
NCT02869295,A Phase 1 Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
NCT02869633,Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
NCT02869789,A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
NCT02870920,Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
NCT02871791,Palbociclib With Everolimus + Exemestane In BC
NCT02871843,Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1)
NCT02872116,Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)
NCT02872714,A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma
NCT02873195,Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02873819,Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
NCT02873962,A Phase II Study Of Nivolumab/ Bevacizumab
NCT02873975,A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
NCT02874404,TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT02874430,Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
NCT02874664,A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
NCT02874742,"Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma"
NCT02875002,Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
NCT02875067,"Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma"
NCT02875548,Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study
NCT02875613,Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
NCT02876003,Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
NCT02876107,A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)
NCT02876224,Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
NCT02876302,Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
NCT02877082,"Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients"
NCT02878785,Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) 
NCT02879162,Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
NCT02879318,"Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma"
NCT02879617,A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
NCT02879695,Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
NCT02879760,Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
NCT02879994,"Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer"
NCT02880020,Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
NCT02880228,"Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant"
NCT02880345,RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
NCT02880371,A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
NCT02881242,Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
NCT02882282,Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
NCT02882321,Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT02883049,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
NCT02883062,"Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer"
NCT02884648,Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery
NCT02885324,Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
NCT02885649,Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
NCT02886065,"A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma"
NCT02886585,Pembrolizumab In Central Nervous System Metastases
NCT02887976,Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
NCT02888665,Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery
NCT02888743,Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
NCT02889861,IMCgp100-401 Rollover Study
NCT02889900,Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)
NCT02890069,"A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat"
NCT02890329,Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT02890355,FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
NCT02890368,Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
NCT02891161,Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
NCT02891603,A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
NCT02892123,Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
NCT02892201,Pembrolizumab in HNSCC With Residual Disease After Radiation
NCT02892318,A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
NCT02892734,Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
NCT02893917,Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02893930,Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
NCT02896335,Palbociclib In Progressive Brain Metastases
NCT02897375,Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
NCT02897765,"A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer"
NCT02897778,Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
NCT02898116,"A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer"
NCT02898207,"Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer"
NCT02899052,Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
NCT02899078,Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
NCT02899195,Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)
NCT02899299,Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)
NCT02899728,"Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer"
NCT02899793,Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
NCT02900157,Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
NCT02900469,Safety Study of Denosumab to Treat Breast Cancer
NCT02900560,Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
NCT02900664,"A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)"
NCT02901548,Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
NCT02901899,"Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
NCT02902484,Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
NCT02903160,"Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)"
NCT02903368,Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy
NCT02903381,Nivolumab + Lenalidomide + Dexamethasone In SMM
NCT02903914,Arginase Inhibitor CB-1158 in Patients With Solid Tumors
NCT02904226,Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC)
NCT02904954,Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer
NCT02905318,Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02905994,Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
NCT02906059,"Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer"
NCT02906332,Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
NCT02906371,Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
NCT02906397,A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)
NCT02906605,"A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer"
NCT02906670,Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
NCT02906696,Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML)
NCT02907099,Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer
NCT02907359,Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
NCT02907918,Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma
NCT02909452,Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
NCT02909777,"Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma"
NCT02909972,Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
NCT02910583,Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
NCT02910700,Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma
NCT02912559,Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability
NCT02912572,"Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer"
NCT02912754,Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
NCT02913196,"Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC"
NCT02913313,A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers
NCT02913417,"Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases"
NCT02913430,Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen
NCT02914327,Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
NCT02915172,Lenvatinib and Capecitabine in Patients With Advanced Malignancies
NCT02915523,Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer
NCT02915666,A Clinical Trial of Patients With Melanoma
NCT02915783,A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
NCT02917993,An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
NCT02918162,Perioperative Chemo and Pembrolizumab in Gastric Cancer
NCT02919449,Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer
NCT02919683,Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
NCT02919969,Pembrolizumab in Refractory Metastatic Anal Cancer
NCT02920008,"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia"
NCT02920450,"Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC"
NCT02920996,Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
NCT02921256,Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
NCT02921269,"Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer"
NCT02921919,Open-Label Extension and Safety Study of Talazoparib
NCT02922777,Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
NCT02923180,Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
NCT02923349,"A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors"
NCT02923531,Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma
NCT02923739,"Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT"
NCT02923921,Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer
NCT02924038,A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
NCT02924233,Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
NCT02924376,Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy
NCT02924766,A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)
NCT02924883,A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy
NCT02925104,"A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors."
NCT02925533,Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
NCT02926768,Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
NCT02926833,A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)
NCT02927262,"A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission"
NCT02927301,"A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)"
NCT02927340,A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
NCT02927769,"A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)"
NCT02927964,"TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma"
NCT02928029,Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
NCT02928224,Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)
NCT02928406,A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
NCT02928575,"Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma"
NCT02928978,Ruxolitinib for Premalignant Breast Disease
NCT02929576,"Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)"
NCT02929862,Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer
NCT02930902,Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer
NCT02932280,Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
NCT02933255,PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer
NCT02933736,Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
NCT02934503,Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NCT02934568,Ribociclib (LEE011) Rollover Study for Continued Access
NCT02935205,Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer
NCT02935309,Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
NCT02935361,Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
NCT02935543,CART19 in Patient With ALL
NCT02935634,A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC)
NCT02935790,Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
NCT02935907,APG-115 in Patients With Advanced Solid Tumors or Lymphomas
NCT02936102,A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
NCT02936206,Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
NCT02936323,PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
NCT02936752,Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
NCT02937272,A Study of LY3200882 in Participants With Solid Tumors
NCT02937675,A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies
NCT02938793,Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
NCT02939274,"An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer"
NCT02939300,Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma
NCT02939651,A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
NCT02939807,A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma
NCT02940223,Effects of Fish Oil and Physical Activity on Fatigue in Colorectal Cancer Patients Receiving Regorafenib
NCT02940301,Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02940496,Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
NCT02941601,A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02941926,Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
NCT02942095,Phase I Study of Ixazomib and Erlotinib in Solid Tumors
NCT02942264,TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
NCT02942290,A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)
NCT02942355,Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
NCT02943317,"Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer"
NCT02943473,Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
NCT02943603,A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
NCT02944396,Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02946996,Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
NCT02947165,Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
NCT02947347,Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
NCT02947386,Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT02947685,"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)"
NCT02948101,Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
NCT02948283,Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
NCT02948426,"Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer"
NCT02949219,Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
NCT02949284,"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery"
NCT02949700,Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
NCT02949843,Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
NCT02950038,Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
NCT02950220,Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950766,"A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma"
NCT02951156,"Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)"
NCT02951819,A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
NCT02952248,A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
NCT02952534,A Study of Rucaparib in Patients With MetA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)
NCT02952573,Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
NCT02952586,Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
NCT02952729,Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2
NCT02952989,A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
NCT02953457,"Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation"
NCT02953509,Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT02953561,Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML)
NCT02953782,Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer
NCT02953860,Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
NCT02954406,"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma"
NCT02954523,Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
NCT02954536,Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
NCT02954653,"A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia"
NCT02954874,Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT02954991,"Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer"
NCT02955069,"Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin"
NCT02955251,"A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors"
NCT02955290,CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT02955394,Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
NCT02955446,Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies
NCT02955758,Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
NCT02956382,Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
NCT02956798,Pazopanib Vs. Local Therapy for Renal Cancer With Metastases
NCT02957968,Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
NCT02959437,Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
NCT02959463,Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
NCT02960022,A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960594,hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
NCT02961283,Study of ASN003 in Subjects With Advanced Solid Tumors
NCT02961374,Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
NCT02961816,Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
NCT02962063,"Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer"
NCT02962804,Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
NCT02963090,Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
NCT02963610,Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
NCT02963831,"A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies"
NCT02964013,Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)
NCT02964078,Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
NCT02964507,Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer
NCT02964559,Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
NCT02965417,Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
NCT02965716,Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
NCT02965885,A Study of TAS-116 in Patients With Solid Tumors
NCT02966587,Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02966730,Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
NCT02966782,A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure
NCT02967692,"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma"
NCT02968940,Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
NCT02969837,"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma"
NCT02970318,A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970539,"Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers"
NCT02970981,Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NCT02971501,Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
NCT02971748,A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy
NCT02971761,Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
NCT02971956,A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer
NCT02972034,Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
NCT02972840,A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
NCT02973113,"Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)"
NCT02973399,Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
NCT02973711,A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
NCT02973997,Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery
NCT02974621,Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
NCT02974647,Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
NCT02974738,A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors
NCT02974803,Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
NCT02975882,"Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors"
NCT02975934,A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
NCT02977468,Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT)
NCT02977689,Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
NCT02977780,INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02978235,A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
NCT02978404,Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
NCT02978443,A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
NCT02978547,The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001)
NCT02978625,Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT02978716,"Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)"
NCT02978859,MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas
NCT02979899,A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)
NCT02979977,Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
NCT02980029,Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer
NCT02981108,"A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC"
NCT02981303,Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
NCT02981342,A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
NCT02981524,Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
NCT02981628,Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981914,Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
NCT02981940,A Study of Abemaciclib in Recurrent Glioblastoma
NCT02982720,Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
NCT02982941,Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
NCT02982954,A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)
NCT02983006,Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
NCT02983045,A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02)
NCT02983578,"AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer"
NCT02983604,GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer
NCT02983799,Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
NCT02984683,Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
NCT02985125,LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
NCT02985554,Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
NCT02985658,Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer
NCT02985957,A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
NCT02987166,HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001)
NCT02987504,Study of Samalizumab in Patients With Advanced Cancer
NCT02987543,Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
NCT02987829,"A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients"
NCT02987959,Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas
NCT02987998,Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
NCT02988440,Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
NCT02988817,HuMax-AXL-ADC Safety Study in Patients With Solid Tumors
NCT02988843,Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
NCT02988960,"A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors"
NCT02988986,"TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer"
NCT02989584,A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer
NCT02989636,"Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma"
NCT02989714,"Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer"
NCT02989844,QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT
NCT02989857,Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
NCT02989870,Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
NCT02990416,A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
NCT02990468,"A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN)"
NCT02990481,A Study of TRK-950 in Patients With Advanced Solid Tumors
NCT02991196,Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
NCT02991651,Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
NCT02991807,RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (PTEN)
NCT02991911,A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
NCT02992483,"Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma"
NCT02992522,"Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma"
NCT02992964,Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
NCT02993159,Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer
NCT02993523,A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993731,A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P)
NCT02993991,Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
NCT02994953,"A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)"
NCT02996110,A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)
NCT02996474,Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
NCT02996825,"Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer"
NCT02997163,An Open-Label Pharmacokinetics and Safety Study of Talazoparib
NCT02997176,An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
NCT02997228,"Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer"
NCT02997761,Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
NCT02998268,Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma
NCT02998476,A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
NCT02998528,A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)
NCT02999477,A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
NCT03000179,Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
NCT03000257,A Study of ABBV-181 in Participants With Advanced Solid Tumors
NCT03000452,A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)
NCT03001882,An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT03002623,CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
NCT03003468,Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
NCT03003520,A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
NCT03003676,"A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade"
NCT03004105,MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
NCT03004183,SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
NCT03004287,2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
NCT03004534,A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201
NCT03005002,Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma
NCT03005782,Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
NCT03006172,"To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer"
NCT03006302,"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer"
NCT03006848,A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
NCT03006926,A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
NCT03007147,Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007407,Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
NCT03007719,[18F]F-AraG Imaging in Bladder Cancer Patients + Atezolizumab
NCT03007732,Pembrolizumab in Combination With Intratumoral SD-101 Therapy
NCT03007979,Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
NCT03008187,SEL24 in Patients With AML
NCT03008278,Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
NCT03008369,Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
NCT03008408,"Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer"
NCT03009201,Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
NCT03009240,Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
NCT03009981,A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NCT03010176,Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)
NCT03011034,Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
NCT03011372,A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
NCT03011814,Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
NCT03012230,Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
NCT03012321,"Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects"
NCT03012477,CISPLATIN + AZD-1775 In Breast Cancer
NCT03013218,A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
NCT03013491,A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
NCT03013998,Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
NCT03014297,Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
NCT03014648,Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)
NCT03014804,Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
NCT03015129,A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
NCT03015740,MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)
NCT03015792,"Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant"
NCT03015896,Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
NCT03016312,"IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen"
NCT03016338,Study of Niraparib in Recurrent Endometrial Cancer
NCT03016377,Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
NCT03016741,Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
NCT03016871,"Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma"
NCT03017833,Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers
NCT03018080,Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy)
NCT03018223,Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
NCT03018249,Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
NCT03018288,Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
NCT03018405,A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK)
NCT03019003,"A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients"
NCT03020030,Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03021460,Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT03021993,Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
NCT03022409,A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT03022565,Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
NCT03022825,QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
NCT03023046,"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma"
NCT03023319,Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
NCT03023423,A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX)
NCT03023722,Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer
NCT03024216,Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
NCT03024437,Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
NCT03024996,A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)
NCT03025035,Pembrolizumab in Advanced BRCA-mutated Breast Cancer
NCT03025256,Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
NCT03026062,Durvalumab and Tremelimumab in Combo Versus Sequential
NCT03026166,A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
NCT03026517,Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma
NCT03027388,"Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma"
NCT03028103,"Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects"
NCT03029403,"Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer"
NCT03029598,"Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT03029780,An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
NCT03029832,A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
NCT03030261,"Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma"
NCT03030287,"A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer"
NCT03030378,Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
NCT03030417,Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
NCT03030885,Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT03031691,A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
NCT03031821,Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
NCT03032107,A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
NCT03032406,"CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer"
NCT03032484,TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
NCT03033225,EUS-guided PDT in Pancreatic Tumors
NCT03033511,A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU)
NCT03033576,Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery
NCT03033914,A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma
NCT03034200,Phase 2 Study of ONC201 in Neuroendocrine Tumors
NCT03035253,A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
NCT03035279,A Study of SC-006 in Subjects With Advanced Cancer
NCT03035331,"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma"
NCT03035630,Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
NCT03035890,Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
NCT03036098,Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03036488,Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
NCT03036904,Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R)
NCT03037385,"Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors"
NCT03037645,"Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers"
NCT03038100,"A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)"
NCT03038477,A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection
NCT03038672,Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03039114,Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
NCT03040973,Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study
NCT03040986,Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
NCT03040999,Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
NCT03041181,Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab
NCT03041311,"Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)"
NCT03041636,Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)
NCT03041688,"MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia"
NCT03041701,Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
NCT03042013,A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
NCT03042611,Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer
NCT03042689,Study of Regorafenib in Patients With Advanced Myeloid Malignancies
NCT03042702,A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
NCT03042819,Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
NCT03042910,A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
NCT03043313,Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER)
NCT03043599,Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
NCT03043664,Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET)
NCT03043807,A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
NCT03043872,Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)
NCT03044613,Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer
NCT03044730,Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
NCT03045328,Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
NCT03047135,"Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis"
NCT03047213,Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
NCT03047473,Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ)
NCT03048136,A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)
NCT03048500,Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT03049618,"Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475"
NCT03050060,"Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer"
NCT03050216,Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
NCT03050398,A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
NCT03050450,Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
NCT03050554,Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
NCT03050814,Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer
NCT03051035,First-in-Human Study of KO-947 in Non-Hematological Malignancies
NCT03051659,A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
NCT03051672,Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC
NCT03052127,Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma
NCT03052205,A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
NCT03052569,Expanded Access to RXDX-105 for Cancers With RET Alterations
NCT03052608,A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03053440,A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
NCT03053544,Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer
NCT03054038,Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
NCT03054363,"Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer"
NCT03054909,QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer
NCT03055013,Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER)
NCT03056001,"Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma"
NCT03056339,Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
NCT03056599,Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma
NCT03056755,"Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant"
NCT03056833,Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
NCT03057106,Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
NCT03057145,Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
NCT03057613,A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck
NCT03057795,Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma
NCT03059147,A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma
NCT03059485,DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
NCT03059823,A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors
NCT03061188,Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes
NCT03061812,Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE)
NCT03063632,Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
NCT03063762,"Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)"
NCT03063944,STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy
NCT03064490,"Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)"
NCT03064854,"PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)"
NCT03064867,Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT03065062,"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors"
NCT03065179,Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients
NCT03065387,"Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation"
NCT03065400,PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
NCT03066206,Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT03066661,"Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions"
NCT03066778,A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
NCT03067051,Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System
NCT03068351,Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
NCT03068455,A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)
NCT03068624,Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma
NCT03069352,A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
NCT03069378,A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
NCT03069469,Study of DCC-3014 in Patients With Advanced Malignancies
NCT03069950,Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
NCT03070002,"Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells"
NCT03070093,Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
NCT03070301,A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
NCT03070392,Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
NCT03070886,Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03071276,Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT03071406,Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
NCT03071757,"A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors"
NCT03071874,Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
NCT03072043,Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
NCT03072160,Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
NCT03072238,"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer"
NCT03073525,Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
NCT03074006,Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS)
NCT03074318,Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
NCT03074513,Atezolizumab and Bevacizumab in Rare Solid Tumors
NCT03075527,A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
NCT03075553,Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
NCT03075696,"A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma"
NCT03075826,A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
NCT03076164,A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
NCT03076203,Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone
NCT03076281,Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
NCT03076372,A Study Evaluating MM-310 in Patients With Solid Tumors
NCT03076554,A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
NCT03077828,Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT03078400,Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer
NCT03078751,Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1)
NCT03079687,"Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer."
NCT03080311,A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
NCT03080974,Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT03081494,Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer
NCT03081702,"A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer"
NCT03082209,A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies
NCT03082300,A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
NCT03082534,Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT03083808,Phase II Trial of Continuation Therapy in Advanced NSCLC
NCT03084471,"An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)"
NCT03084640,Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma
NCT03085056,Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
NCT03085095,A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO)
NCT03085147,A Dye for the Detection of Cancer of the Tongue and Mouth
NCT03085719,Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
NCT03085849,SGI-110 Plus Durvalumab/Tremelimumab in SCLC
NCT03085914,A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207)
NCT03086369,A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
NCT03086733,Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore)
NCT03087019,Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
NCT03087071,Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer
NCT03087448,Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT03087591,"APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery"
NCT03087760,Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
NCT03088176,Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
NCT03088878,A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
NCT03088930,Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
NCT03089606,Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker
NCT03089645,MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors
NCT03090165,Ribociclib and Bicalutamide in AR+ TNBC
NCT03090737,Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907)
NCT03091192,Savolitinib vs. Sunitinib in MET-driven PRCC
NCT03091257,A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091478,Pembrolizumab in Patients With Leptomeningeal Disease
NCT03091660,Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
NCT03092323,A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)
NCT03092453,Dendritic Cell Vaccination in Patients With Advanced Melamona
NCT03092635,AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy
NCT03092674,"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome"
NCT03092856,Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
NCT03092934,A Study of AK-01 in Solid Tumors
NCT03093116,"A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements"
NCT03093155,Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
NCT03093272,A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
NCT03093428,Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
NCT03093870,Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
NCT03093922,A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
NCT03094052,"Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy"
NCT03094169,AVID100 in Advanced Epithelial Carcinomas
NCT03094611,Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia
NCT03094637,Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS)
NCT03095248,Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
NCT03095352,"A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease"
NCT03095612,Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
NCT03095781,Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
NCT03097328,Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
NCT03098160,Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
NCT03098550,A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread
NCT03098836,Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer
NCT03099109,A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors
NCT03099161,Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
NCT03099174,This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
NCT03099356,"Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer"
NCT03099499,Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
NCT03099564,Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
NCT03101254,LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
NCT03101566,Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
NCT03101748,3HT With Taxol for Metastatic Breast Cancer
NCT03101839,Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
NCT03102606,Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1)
NCT03104270,Combination Study for High Risk Multiple Myeloma Patients
NCT03104439,Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT03104491,Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
NCT03104699,Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer
NCT03105336,A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)
NCT03106077,Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)
NCT03106415,Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT03106428,A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies
NCT03106610,Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
NCT03106779,"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs"
NCT03107182,Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events
NCT03107780,MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma
NCT03107988,Study of Lorlatinib (PF-06463922)
NCT03108066,PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
NCT03108131,Cobimetinib and Atezolizumab in Advanced Rare Tumors
NCT03109015,Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET)
NCT03109158,NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT03109301,A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
NCT03109873,Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer
NCT03110107,First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors
NCT03110354,DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
NCT03110562,"Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)"
NCT03110822,"A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients"
NCT03110978,Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR
NCT03111732,"Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)"
NCT03111901,Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
NCT03111992,"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma"
NCT03112174,Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
NCT03112590,Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
NCT03113188,"CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors"
NCT03113487,"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer"
NCT03114527,Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)
NCT03115801,A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
NCT03116971,Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
NCT03117309,Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
NCT03117751,Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03118349,Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy
NCT03119428,A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03119467,"Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma"
NCT03120676,Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
NCT03120832,Phase 1 Trial of PAN-301-1 in Cancer Patients
NCT03121352,"Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer"
NCT03121417,Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer
NCT03121677,Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
NCT03122197,Study of Letrozole in Recurrent Gliomas
NCT03122496,Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
NCT03122509,"A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer"
NCT03122548,"Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers"
NCT03122717,Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NCT03123055,A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22)
NCT03123744,Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
NCT03123783,CD40 Agonistic Antibody APX005M in Combination With Nivolumab
NCT03123939,Expanded Treatment Protocol in Acute Lymphoblastic Leukemia
NCT03123978,Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
NCT03125200,Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
NCT03125239,Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT03125902,A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)
NCT03125928,"Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer"
NCT03126019,"An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)"
NCT03126110,"Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies"
NCT03126331,Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients
NCT03126461,SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
NCT03126591,A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
NCT03126630,Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
NCT03126916,Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
NCT03127098,"QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer"
NCT03127735,BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)
NCT03128034,"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome"
NCT03128047,HUMC 1612: Optune NovoTTF-200A System
NCT03128619,"Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer"
NCT03128879,Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)
NCT03129061,Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT03130439,"Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer"
NCT03130764,Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
NCT03130959,An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908)
NCT03131037,Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
NCT03131206,A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
NCT03131908,Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
NCT03132454,Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias
NCT03132467,Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer
NCT03132636,"PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy"
NCT03133221,1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
NCT03133390,Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients
NCT03134131,Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma
NCT03134638,A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors
NCT03135171,Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
NCT03135262,A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03136055,Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
NCT03136146,"Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)"
NCT03136406,QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03136497,A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT03137771,Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03138161,"Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma"
NCT03138499,"Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,"
NCT03138512,A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914)
NCT03138889,A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer
NCT03139331,PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
NCT03139370,A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
NCT03139747,UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
NCT03139916,Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
NCT03140670,Rucaparib in BRCA1/2 or PALB2 Mutated Pancreatic Cancer
NCT03141034,Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT03141177,A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)
NCT03141671,Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
NCT03141684,Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery
NCT03142334,Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
NCT03143153,A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648)
NCT03143270,A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
NCT03143985,TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
NCT03144245,Study of AMV564 in Patients With AML
NCT03144661,An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
NCT03144674,A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
NCT03144778,Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)
NCT03145181,"Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma"
NCT03145558,TATE Versus TACE in Intermediate Stage HCC (TATE)
NCT03146650,Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer
NCT03147196,Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
NCT03147287,Palbociclib After CDK and Endocrine Therapy (PACE)
NCT03147612,Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
NCT03147885,Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
NCT03148275,"Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery"
NCT03148418,A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study
NCT03148795,A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
NCT03149003,A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G)
NCT03149029,Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
NCT03149120,Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
NCT03149159,"Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab"
NCT03149549,PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
NCT03149822,Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
NCT03150056,Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer
NCT03150329,"Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma"
NCT03150693,Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
NCT03150810,"Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors"
NCT03150836,"Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer"
NCT03150862,A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma
NCT03151304,A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
NCT03151408,An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
NCT03152370,Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1)
NCT03153202,Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
NCT03153410,"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas"
NCT03153462,Axicabtagene Ciloleucel Expanded Access Study
NCT03153982,Ruxolitinib in Operable Head and Neck Cancer
NCT03154281,Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast
NCT03154294,Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
NCT03155620,Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas
NCT03155997,A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer
NCT03156114,This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
NCT03157089,Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO)
NCT03157128,"Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer"
NCT03158064,"Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors"
NCT03158103,A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
NCT03158129,Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection
NCT03158883,Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients
NCT03159117,Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
NCT03159195,Ibrance Real World Insights [IRIS] (IRIS)
NCT03160079,Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts
NCT03161223,"Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma"
NCT03161431,SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
NCT03162224,Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer
NCT03162536,"Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies"
NCT03162562,The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
NCT03162627,Selumetinib and Olaparib in Solid Tumors
NCT03162731,"Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer"
NCT03164057,A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT03164603,"NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors"
NCT03164616,Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON)
NCT03164772,Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC
NCT03165721,"A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer"
NCT03165994,APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
NCT03166085,PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
NCT03166254,Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer
NCT03166631,A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
NCT03168100,"2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma"
NCT03168438,NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma
NCT03168464,Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)
NCT03170206,Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
NCT03170960,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03171025,Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)
NCT03172624,Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
NCT03172754,Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT03172936,Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
NCT03173248,Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)
NCT03173560,Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma
NCT03173950,Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
NCT03174197,Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM)
NCT03174275,"Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma"
NCT03175172,Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM
NCT03175224,CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation
NCT03175432,Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases  (BEAT-MBM)
NCT03178071,Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations
NCT03178201,TGR1202 in Relapsed and Refractory Follicular Lymphoma
NCT03178552,A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST)
NCT03178851,A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy
NCT03179436,"Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)"
NCT03179904,"FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer"
NCT03179917,Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
NCT03179930,Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
NCT03181100,Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas
NCT03181126,A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia
NCT03181308,Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
NCT03184558,BGB324 in Combination With Pembrolizumab in Patients With TNBC
NCT03184571,BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC
NCT03184870,A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
NCT03187288,A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT03188965,First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
NCT03189186,Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
NCT03189719,First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
NCT03190174,Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma
NCT03190213,Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC)
NCT03190278,Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia
NCT03190915,Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
NCT03190941,Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients
NCT03190967,T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
NCT03191149,Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
NCT03191786,A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy
NCT03192202,AFM13 in Relapsed/Refractory Cutaneous Lymphomas
NCT03192345,"A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors"
NCT03193190,A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT03193437,Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy
NCT03193853,TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
NCT03193918,Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
NCT03194373,Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT03194867,Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
NCT03194893,A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
NCT03194932,Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT03195699,"Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers"
NCT03196232,Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
NCT03196401,A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma
NCT03197506,Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
NCT03197935,A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031)
NCT03199040,Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
NCT03199885,"Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer"
NCT03200847,Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
NCT03201250,Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
NCT03201458,Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery
NCT03201913,Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy
NCT03202316,Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
NCT03202940,A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
NCT03203304,Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma
NCT03203369,Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)
NCT03203473,Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
NCT03204188,"Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"
NCT03204812,Tremelimumab + Durvalumab Chemotherapy Naive CRPC
NCT03205046,A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
NCT03205176,Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas
NCT03206047,"Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"
NCT03206073,A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
NCT03206177,Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
NCT03206203,Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
NCT03206645,PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy
NCT03207334,iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001)
NCT03207347,A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001)
NCT03207529,Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
NCT03207555,Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
NCT03208712,Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
NCT03209401,Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies
NCT03210662,Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL)
NCT03210714,"Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations"
NCT03211117,"Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer"
NCT03211416,Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
NCT03211988,Entinostat Neuroendocrine (NE) Tumor
NCT03212274,"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations"
NCT03213041,Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT03213626,Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
NCT03213652,"Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations"
NCT03213665,"Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations"
NCT03213678,"Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations"
NCT03213691,"Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations"
NCT03213704,"Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions"
NCT03214250,Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
NCT03214562,Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT03215095,RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers
NCT03215264,"Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer"
NCT03215511,Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers
NCT03215706,A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)
NCT03215810,Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
NCT03216499,HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
NCT03217071,Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
NCT03217253,Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
NCT03217266,MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
NCT03217747,Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies
NCT03217838,"Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients."
NCT03218826,PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
NCT03219047,The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response
NCT03219268,A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
NCT03219333,A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)
NCT03220009,"Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma"
NCT03220035,"Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations"
NCT03220477,Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
NCT03220646,The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.
NCT03221400,PEN-866 in Patients With Advanced Solid Malignancies
NCT03221426,Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
NCT03221634,Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
NCT03222076,Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)
NCT03223155,"Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer"
NCT03223610,"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma"
NCT03223779,Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
NCT03224767,Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
NCT03224871,A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.
NCT03225105,M3541 in Combination With Radiotherapy in Subjects With Solid Tumors
NCT03225547,Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
NCT03225664,BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC)
NCT03226249,PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
NCT03227432,An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
NCT03228186,Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
NCT03228537,"Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma"
NCT03228667,"QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy"
NCT03229200,Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229278,Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
NCT03230318,ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
NCT03231306,Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI)
NCT03232307,Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)
NCT03233204,"Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes"
NCT03233347,"Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma"
NCT03233711,Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233724,"The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer"
NCT03235869,Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
NCT03236857,A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
NCT03236935,Phase Ib of L-NMMA and Pembrolizumab
NCT03237390,Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
NCT03237572,Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48)
NCT03237780,Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
NCT03238196,"Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer"
NCT03238248,Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors
NCT03238365,Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
NCT03238495,Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
NCT03238638,"A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy"
NCT03238703,"Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer"
NCT03239145,Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
NCT03239340,A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
NCT03240016,Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer
NCT03240861,Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT)
NCT03241173,A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
NCT03241745,A Study of Nivolumab in Selected Uterine Cancer Patients
NCT03241810,Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
NCT03241927,Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
NCT03242915,Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)
NCT03243331,An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
NCT03244384,Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
NCT03245151,"Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors"
NCT03245541,Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad)
NCT03245736,Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
NCT03245892,A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer
NCT03246906,Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
NCT03246958,Nivolumab Plus Ipilimumab in Thyroid Cancer
NCT03247088,Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation
NCT03247283,Pharmacokinetics and Metabolism Study in Healthy Male Participants
NCT03247712,Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
NCT03248479,Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies
NCT03248492,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
NCT03249792,Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
NCT03250273,A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
NCT03250299,Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
NCT03250676,"Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer"
NCT03251924,A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
NCT03253679,WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
NCT03254927,A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
NCT03255018,"Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas"
NCT03255096,"A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"
NCT03256045,"Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma"
NCT03256136,"A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer"
NCT03257163,"Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer"
NCT03257267,Study of REGN2810 in Adults With Cervical Cancer
NCT03257722,Pembrolizumab + Idelalisib for Lung Cancer Study
NCT03257761,"Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer"
NCT03258008,Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
NCT03258398,A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
NCT03258515,A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
NCT03258554,Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin
NCT03258593,Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
NCT03259425,"Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma"
NCT03259503,Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas
NCT03259633,An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
NCT03259867,Combination of TATE and PD-1 Inhibitor in Liver Cancer
NCT03260504,Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
NCT03261999,"Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer"
NCT03262779,Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
NCT03263026,Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1
NCT03263429,Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
NCT03263572,Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
NCT03263650,Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
NCT03263936,Epigenetic Reprogramming in Relapse/Refractory AML
NCT03264066,A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors
NCT03264404,Azacitidine and Pembrolizumab in Pancreatic Cancer
NCT03267186,Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
NCT03267836,Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma
NCT03267888,Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
NCT03268057,VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
NCT03269669,"Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma"
NCT03270176,A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
NCT03271047,Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
NCT03271372,Adjuvant Avelumab in Merkel Cell Cancer (ADAM)
NCT03272464,Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
NCT03273153,A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
NCT03274258,Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
NCT03274492,"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma"
NCT03274661,Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors
NCT03275597,Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
NCT03276832,Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
NCT03277209,"To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas"
NCT03277352,INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
NCT03277482,"Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer"
NCT03277638,Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma
NCT03278379,Avelumab in G2-3 NET (NET-002)
NCT03278405,Avelumab in G3 NEC (NET-001)
NCT03278782,Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
NCT03279250,Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence
NCT03279692,Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
NCT03280563,A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
NCT03281369,A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA)
NCT03281382,Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer
NCT03282344,A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
NCT03282396,Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease
NCT03283137,Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
NCT03283605,Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
NCT03283631,Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
NCT03283696,"A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma"
NCT03283917,"Study of Daratumumab, Ixazomib, and Dexamethasone in Previously Treated Amyloid Light Chain (AL) Amyloidosis"
NCT03283943,PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
NCT03284957,Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
NCT03285321,Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
NCT03285412,"CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer"
NCT03285607,"MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer"
NCT03286114,Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
NCT03286296,LZM009 to Treat Patients With Advanced Solid Tumors
NCT03286530,Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
NCT03287050,"Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma"
NCT03288350,mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)
NCT03288493,P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
NCT03289039,"A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer"
NCT03289741,A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
NCT03289962,A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT03290079,Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas
NCT03290937,"Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer"
NCT03291054,Epacadostat and Pembrolizumab in Patients With GIST
NCT03291938,Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma
NCT03292133,A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
NCT03292172,"A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer"
NCT03294694,Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
NCT03295227,Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
NCT03295396,ONC201 in Adults With Recurrent High-grade Glioma
NCT03295942,A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
NCT03296696,Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma
NCT03297424,A Study of PLX2853 in Advanced Malignancies.
NCT03298087,Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
NCT03298451,Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT03298958,Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
NCT03298984,Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
NCT03299088,Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations
NCT03299946,Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
NCT03300557,Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer
NCT03301896,Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
NCT03302234,Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)
NCT03302247,Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
NCT03304080,"Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast"
NCT03304639,Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
NCT03305445,Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
NCT03306420,First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
NCT03307603,Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
NCT03307785,Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042
